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A Novel Mechanism of Skin Tumor Promotion Involving Interferon-gamma (IFNγ)/Signal
Transducer and Activator of Transcription-1 (Stat1) Signaling in Epidermis
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Supervisory Professor: John DiGiovanni, Ph.D.

The JAK-STAT pathway is a major signaling pathway involved in many biological
processes including proliferation, apoptosis, and differentiation. Aberrant
expression of STATs has been reported in multiple human cancers and murine
mouse models of tumorigenesis. Previous studies from our lab and others have
established a critical role for Stat3 in epithelial tumorigenesis, but the role of
Stat1 is largely unknown. The current study was designed to explore the role of
Stat1 during multistage skin carcinogenesis. Topical treatment with both TPA
and the anthrone derivative chrysarobin (CHRY) led to rapid phosphorylation of
Stat1 on both tyrosine (Tyr701) and serine (Ser727) residues in epidermis.
CHRY treatment also led to upregulation of unphosphorylated Stat1 (uStat1) at
later time points. In addition, CHRY treatment also led to upregulation of IRF-1
mRNA and protein which was dependent on Stat1. Further analyses
demonstrated that topical treatment with CHRY but not TPA upregulated
interferon-gamma (IFNγ) mRNA in the epidermis and that the induction of both
IRF-1 and uStat1 was dependent on IFNγ signaling. Stat1 deficient (Stat1-/-)
mice were highly resistant to skin tumor promotion by CHRY. In contrast, the
tumor response (in terms of both papillomas and squamous cell carcinomas) was
similar in Stat1-/- mice and wild-type littermates with TPA as the promoter.
Histological evaluation of the proliferative response confirmed the data obtained
vi

from the tumor study for both TPA and CHRY. In addition, maximal induction of
both cyclooxygenase-2 and inducible nitric oxide synthase in epidermis following
treatment with CHRY was also dependent on the presence of functional Stat1.
Following CHRY treatment, Stat1-/- mice exhibited reduced macrophage
infiltration and reduced production of many immune cell derived
chemokines/cytokines. These studies define a novel mechanism associated with
skin tumor promotion by the anthrone class of tumor promoters involving
upregulation of IFNγ signaling in the epidermis and downstream signaling
through activated (phosphorylated) Stat1 and subsequent upregulation of IRF-1
and uStat1.
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Chapter 1: Introduction
1.1 Signal Transducer and Activators of Transcription
Signal Transducers and Activators of Transcription (STATs) represent a family
of conserved transcription factors that transduce extracellular signals from the cellular
membrane of the cell to the nucleus. These latent cytoplasmic transcription factors
consist of seven members: Stat1α/β, Stat2, Stat3α/β, Stat 4, Stat5A, Stat5B and Stat6,
7(1). STATs can generally be classified into two groups according to their function. One
group consists of Stat2, Stat4 and Stat6, which are activated by various cytokines and
play distinct roles in T-cell development and interferon signaling. The other group
includes Stat1, Stat3 and Stat5, which regulate important aspects of cellular growth,
proliferation and apoptosis (2).
Our understanding of STAT signaling began over 40 years ago when Alick
Isaacs and Jean Lindenmann et al reported on a phenomenon in the field of ‘‘virus
interference,’’ that described a condition that disrupted virus formation (3) (4). Over the
years the understanding of this pathway has grown to encompass all aspects of its
function and can be seen in the nomenclature itself. The aptly named STATs represent
a class of molecules with dual functionality. Stat proteins not only provide a means to
transmit signals from the exterior of the cell to the nucleus but they also directly
participate in gene regulation by binding to DNA.
1.2 Structure of STATs
STATs are proteins composed of approximately 850 amino acids, with the
exception of Stat2 and Stat6, which have between 750 and 800 amino acids and range
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in size from 90-115kDA (5). STATs share several highly conserved domains, which
are important for their respective functions. STATs contain an N-terminal
oligomerization domain, which is involved in stabilizing protein-protein interactions. This
domain is also responsible for dimer-dimer interactions that facilitate the formation of
STAT tetramers or oligomers. STATs contain a DNA-binding domain (DBD) that
confers specificity of binding to cognate DNA sequences of target gene promoters. A
linker domain resides between the DBD and the SRC homology-2 (SH2) domain. The
function of this domain has not been fully characterized, although mutations within this
domain affect the stability of DNA binding (6). The SH2 domain contains the critical
tyrosine residues (Y701 for Stat1, Y690 for Stat2, Y705 for Stat3, Y693 for Stat4, Y695
for Stat5, and Y641 for Stat6) that are required for Stat recruitment to the cytoplasmic
tail of the phosphorylated receptor. Phosphorylation of this site leads to activation
(dimerization) of STATs. Differences in the SH2 domain confer selectivity to different
cytokine receptors of each respective STAT protein [reviewed in (7)]. The
transactivation domain (TAD) of each STAT is located in the carboxyl terminal region.
The TAD domains contain the serine phosphorylation site that is responsible for
maximal transcriptional activation (Bowman Oncogene 2000). Some STATs, in
particular Stat1 and Stat3, have naturally occurring splice variants (Stat1β and Stat3β),
which lack a portion of the C-terminal transactivation domain. These variants can
potentially act as dominant-negative forms (8, 9). Figure 1 shows the structure of a
representative STAT (Stat1) dimer bound to DNA (panel a) as well as a diagram of the
various structural domains (panel b).
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Figure 1. The Core Structure of a STAT1 Dimer Bound to DNA.
(a) The core structure (amino acids 130–712) shows binding of a
STAT1 dimer to DNA and the location of binding sites of various
proteins in various domains. STATs share several highly conserved
domains that are important for their respective function. (b) STATs
contain an N-terminal domain (N-terminus), a Coiled-Coiled domain
(CC), a DNA-binding Domain (DBD), a Linker Domain, a SrcHomology-2 domain (SH2 Domain) and a transactivation domain
(TAD). Reproduced with the permission of the journal Nature
Reviews: Molecular Cell Biology. Levy DE and Darnell JE Jr.
(2002)“Stats: transcriptional control and biological impact.”Nature
Reviews Molecular Cell Biology 3, 651-662.
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1.3 Activation of STATs
STATs are activated by a variety of stimuli, including cytokines, growth factors,
and hormones. Cytokines represent a large number of soluble molecules that regulate
cellular growth, differentiation, and immune responses. Cytokines are classified as
Type I (i.e. IL-2, IL-3, IL-4) and Type II (interferons and IL-10) and signal via cytokine
receptors that contain no intrinsic enzymatic kinase activity, but accomplish
phosphorylation of STATs via receptor associated Janus Kinases (JAKs). The JAK
family of receptor associated tyrosine kinases consist of four members: JAK1, JAK2,
JAK3, and tyrosine kinase 2 (Tyk2), which are activated by receptor dimerization after
ligand binding (10).
STATs are also activated by growth factor receptors such as epidermal growth
factor (EGF) receptor, insulin-like growth factor (IGF)-1 receptor, platelet-derived
growth factor (PDGF) receptor, hepatocyte growth factor (HGF) receptor, and colonystimulating factor- 1 (CSF-1) receptor, all of which possess an intrinsic tyrosine kinase
activity (11). In addition to cytokine and growth factor receptor activation, STATs can
also be activated by non-receptor tyrosine kinases such as SRC and ABL. STATs can
also be activated by seven transmembrane domain receptors, such as angiostatin II,
serotonin and α-melatonin (12).
Following ligand binding, a conformational change occurs on the cytoplasmic tail
of the receptor inducing autophosphorylation and transphosphorylation of the
associated JAK. This is followed by phosphorylation of the cytoplasmic tail of the
receptor, which provides docking sites for the recruitment of STAT molecules that
recognize phosphotyrosine via their phosphotyrosine binding domain (PTB) or SH2
4

domain (13). Once recruited to the SH2 domain of the receptor the STAT molecules
are subsequently phosphorylated on tyrosine residues (14). Tyrosine phosphorylated
STATs subsequently form homo/hetero dimers or heterotrimeric complexes that
translocate to the nucleus where they bind to cognate DNA sequences and activate
gene transcription. Figure 2 is a schematic depicting activation of STATs via receptors
such as growth factor receptors, cytokine receptors and G-protein coupled receptors.

5

Figure 2. Activation of the JAK-STAT Pathway via Receptor
Signaling. A conceptual diagram of the multiple mechanisms for
tyrosine phosphorylation of STATs by Janus kinases (JAKs) or other
protein tyrosine kinases (PTKs) that are intrinsic to receptors or that
are present in the cytoplasm or nucleus. Tyrosine phosphorylation
generates STAT dimers that can bind specific DNA targets. The
JAK-STAT pathway is activated by a variety of stimuli. STATs can
be activated by growth factor receptors that possess intrinsic kinase
activity. They may also be activated by cytokine receptors which
employ the use of a family of receptor associated kinases called
Jaks (Jak1, Jak2, Jak2, Tyk2). STATs may also be activated by
non-receptor tyrosine kinases such as Src and ABL. Reproduced
with the permission of the journal Nature Reviews: Immunology.
Reich NC and Liu L. (2006) “Tracking STAT nuclear traffic.” Nature
Reviews Immunology 6, 602-612.
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Previous studies also reported that STATs undergo cycles of activationinactivation. STAT activity is coupled with nuclear-cytoplasmic shuttling and regulated
by posttranslational modifications such as phosphorylation and acetylation. Nuclear
retention of STATs is dependent upon their phosphorylation status. For example,
phosphorylation of Stat1 on tyrosine 701 results in nuclear translocation, whereas
acetylation of lysine residues 410 and 413 leads to increased dephosphorylation. Thus,
acetylation results in Stat1 inactivation (15). After binding to DNA and activating gene
transcription, STAT inactivation occurs rapidly and the unphosphorylated STAT
molecule is exported out of the nucleus.
1.4 Negative Control of STATs
STAT activation is a transient process. Within hours the activating signals
subside and STATs are again in an inactive state. The JAK-STAT signaling pathway is
negatively regulated by two nuclear regulators, protein inhibitors of activated STATs
(PIAS) and protein tyrosine phosphatases (PTPs) and one cytoplasmic regulator,
suppressor of cytokine signaling (SOCS). There is data to suggest that PTPs also act
at the membrane level by dephosphorylating activated JAKs at the receptor. PIAS
interact exclusively with tyrosine-phosphorylated forms of Stat proteins, thereby
preventing DNA binding. PTPs, which contain SH2 domains, negatively regulate
activated STATs by interacting and directly dephosphorylating STATs in the nucleus.
SOCS are cytokine-induced proteins that are recruited to activated receptor complexes
to regulate signaling. SOCS proteins inhibit signaling by directly binding to activated
JAKS, thereby competing for STAT binding and/or by targeting activated JAKs for
ubiquitin-mediated proteasomal degradation (16). Figure 3 shows the major pathways
involved in negative regulation of STAT signaling.
7

Figure 3. Negative Regulators of STAT Signaling. Stat activation
is a transient process and therefore requires negative regulation.
The Janus kinase (JAK)–signal transducer and activator of
transcription (STAT) pathway is regulated at many levels. Two
nuclear regulators, protein inhibitors of activated STATs (PIAS),
protein tyrosine phosphatases (PTP) and one cytoplasmic regulator,
suppressor of cytokine signaling (SOCS), negatively regulate the
JAK-STAT signaling pathway. PIAS bind directly to activated
STATs whereby they block the transcription of downstream target
genes. PTP dephosphorylate activated STATs thereby facilitating
their export out of the nucleus. The SOCS class of proteins acts in a
classical negative feedback loop. They are transcriptionally
upregulated after JAK-STAT pathway activation. SOCS negatively
regulate STAT signaling by binding to activated JAKS, thereby
blocking JAK activity. Reproduced with the permission of the journal
Nature Reviews: Immunology. Shuai K, and Liu B. (2003)
“Regulation of JAK-STAT signaling in the immune system.”Nature
Reviews Immunology 3, 900-911.
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1.5 Interferon Signaling
Isaacs and Lindenmann identified interferon (IFN), the first cytokine discovered,
during their seminal studies over 50 years ago (3, 4). IFNs are a family of multifunctional proteins that were first discovered due to their ability to interfere with viral
replication. IFNs are historically classified as Type I and Type II, based on receptor
specificity and sequence homology. Type I IFNs are comprised of multiple interferonalpha (α) subtypes (14-20 depending species), interferon beta (β), interferon omega (ω)
and interferon tau (τ). All Type I IFNs are structurally related and bind to a
heterodimeric receptor, IFNAR (comprised of IFNAR1 and IFNAR2).
Type II IFNs are represented by only one cytokine, which is IFN gamma
(γ)(IFNγ). IFNγ binds to a different receptor than that of Type I IFNs. The IFNγR is
comprised of two ligand-binding IFNγR1 chains that are associated with two signaltransducing IFNγR2 chains (17). IFN receptors, like other cytokine receptors, possess
no intrinsic kinase activity and therefore depend on receptor-associated kinases to
phosphorylate their substrates. IFNs also employ JAK family tyrosine kinases as
described above (17).
Binding of the Type I IFNs, such as IFNα, to its receptor induces dimerization of
the two subunits and leads to the auto and transphosphorylation of TYK2 and Jak1.
Activated JAKs then phosphorylate the receptor cytoplasmic domain on tyrosine
residues, which provides a docking site for Stat1 or Stat2. Stat1 or Stat2 is then able to
bind and is subsequently phosphorylated on tyrosine (Y701 for Stat1; Y690 for Stat2)
by JAKs, which in turn allows the recruitment of Stat1. Stat1 is subsequently
phosphorylated on tyrosine, which allows the release of Stat1/Stat2 heterodimer. The
9

Stat1/Stat2 heterodimer is now available to form a heterotrimeric complex containing
p48 (also known as ISGF3 or IRF9), thus forming the ISGF3 complex. The ISGF3
transcription factor complex translocates to the nucleus where it binds to DNA
containing the ISRE (IFNα-stimulated gene response element) sequence in the
promoter region of its target genes(18)
Upon binding of IFNγ to its receptor, IFNγR1 and IFNγR2 dimerize which leads to
the auto and transphosphorylation of JAK1 and JAK2. The JAKs in turn cause the
phosphorylation of the cytoplasmic domain of the IFNγR1 tail, which provides SH2
docking sites for STAT1. Once phosphorylated, Stat1 homodimers translocate to the
nucleus and bind to DNA containing the GAS (IFNγ-activated site) sequences. Figure
4 illustrates the canonical signaling pathways for both Type I and Type II IFNs.

10

Figure 4. Interferon Receptor Activation by Classical JAK-STAT
signaling. IFNs are historically classified as Type I and Type II, which is
based on receptor specificity and sequence homology. Type I IFNs are
comprised of multiple interferon-alpha (α) subtypes, interferon beta (β),
interferon omega (ω), and interferon tau (τ). Type II IFNs are represented
by only one cytokine, IFNγ. JAK1 and TYK2 activation is associated with
the type I IFN receptor activation. Which results in tyrosine phosphorylation
of STAT2 (signal transducer and activator of transcription 2) and STAT1;
which results in the formation of STAT1–STAT2–IRF9 (IFN-regulatory
factor 9) complexes. IFNs also induce the formation of Stat1 homodimers
that bind to IFN-gamma activated sequences (GAS) elements located in
the promoter region ISGs, thereby initiating the transcription of these
genes. Reproduced with the permission of the journal Nature Reviews:
Immunology. Platanias LC. (2005) “Mechanisms of type-I- and type-IIinterferon-mediated signaling.” Nature Reviews Immunology 5, 375-386.
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1.6 Stat1 and Immune Function
Stat1 was the first member of the STAT family of proteins discovered. Stat1 has
been shown to be the principal transducer of Type I (α and β) and Type II (γ) IFNs. The
IFNγ/Stat1 axis has been shown to regulate many biological processes such as cellular
growth, immune response, and even inflammation [reviewed in (5)]. Type I and Type II
IFNs play a complementary and non-redundant role in defense against a broad
spectrum of viral and bacterial pathogens. IFNs play a vital role in both the innate and
humoral immune response. Various immunocytes such as lymphocytes, dendritic cells
and macrophages produce IFNs in response to invading pathogens (19).
Activation of the IFNγ/Stat1 pathway is critical to processing and presentation of
tumor antigens. Stat1 regulates key components of the immunoediting machinery
such as major histocompatibility complex (MHC) class I and II (20). MHC class
proteins are necessary for immune cells such as lymphocytes to display phagocytosed
tumor antigens on their cell surface. Dysregulation of Stat1-dependent expression of
MHC and other components such as the MHC class II transactivator CIITA, leads to
defective antigen presentation (21).
1.7 Stat1 and Growth Arrest/Growth Inhibition
Stat1 also plays a role in cellular growth, as its activation generally evokes an
anti-proliferative program. Stat1 has the ability to regulate the cell cycle at various
points of its progression. Previous reports have shown that Stat1 activation may inhibit
cell cycle progression by blocking oncogenic signals such as c-Myc and various cyclins
(A, B, D2, D3 and E) (22). Stat1 has also been shown to negatively affect the cell cycle
by up-regulating various tumor suppressor proteins, such as the cyclin-dependent
12

kinase inhibitors (CKIs), p21 WAF1/CIP1 and p27/KIP1 [reviewed in(23)]. The
activation of these CKIs ultimately leads to G0/G1 cell cycle arrest. In the prostatic
cancer cell lines DU145, LNCaP, and PC-3 it was reported that treatment with IFNγ
resulted in the down-regulation of the proto-oncogene (Her)-2/neu, which was shown to
be Stat1-dependent (24).
1. 8 Stat1 and Apoptosis
The importance of Stat1 in the apoptotic response has been supported by the
fact that pro-apoptotic properties of IFNs are largely mediated by STAT signaling.
Stat1 has the ability to promote apoptosis by regulating both transcription-dependent
and independent mechanisms. Stat1 promotes apoptosis by inducing both initiator and
effector caspases. Stat1 can induce the expression of caspases 1 and 11, which are
required for activation of the effector caspases, 3 and 7, (25, 26). Activation of Stat1 via
IFNγ signaling induces the expression of several surface cell death receptors and their
ligands, such as Fas/FasL, TRAIL and its receptor Killer/DR5, (27-29). Stat1 can also
regulate other pro-apoptotic genes such as XIAP-associated factor- (XAF)-1, (30) and
IFN-induced transmembrane protein 1 (IFITM1), (31). It is noteworthy that Stat1 can
also negatively regulate the expression of pro-survival genes such as Bcl-2 and Bcl-xl
(32).
Stat1 can serve as a co-activator of pro-apoptotic signaling. In this regard, Stat1 acts
as a co-activator by interacting with tumor necrosis factor (TNF)-α receptor 1 (TNFR1)
and TNFR1-associated death domain protein (TRADD). Acting as a component in this
complex, Stat1 serves to inhibit NF-κB-mediated pro-survival signaling (33). Stat1 is
required for DNA damage-induced apoptosis through its direct interaction with p53 (34).
13

In addition Stat1 can also act on the negative regulator of p53, Mdm2, by targeting it for
proteosomal degradation (34).
1.9 Stat1 and Angiogenesis
Angiogenesis plays an important role in the development of cancer (35).
Neovascularization is vital to the progression of tumor development, and may also
serve as a prognostic indicator of metastatic potential. Stat1 has been shown to inhibit
vascular endothelial growth factor (VEGF), a potent signaling molecule that promotes
the formation of new blood vessels to tissues with inadequate oxygen supply. Stat1
inhibits the action of VEGF by inhibiting factors required for VEGF-induced tube
formation, including urokinase plasminogen activator, angiopoetin-2, tissue inhibitor of
matrix metalloproteinase (TIMP)-1, and VEGFR-2 (36). In addition, Stat1 can activate
the production of the CXC chemokine family member, interferon-inducible protein IP10
(CXCL10). IP-10, a known anti-angiogenic gene, blocks the production of fibroblast
growth factor (FGF)-β, (37) and inhibits endothelial cell motility (38). Endothelial cell
motility is a critical component of the angiogenic response.

1.10 Potential Role of Unphosphorylated Stat1 (uStat1)
Recently, it has been found that Stats 1 and 3 (and possibly other Stats) may
play important roles in mediating gene expression in the absence of tyrosine
phosphorylation (39, 40). Stat1 and Stat3 genes are targets of activated
(phosphorylated) Stat1 and Stat3 proteins, respectively (41). As a result, cytokine
activation of Stat1 or Stat3 (e.g., IFNγ or IL-6, respectively), leads to the induction and
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accumulation of uStats 1 and 3, which may persist for days after p-Stat levels have
subsided (40). In addition, induction of the Stat1 target gene, IRF-1, aids in the
continued accumulation of uStat1 in response to IFNγ. It is well-documented that
uStats 1 and 3 can act as transcription factors to regulate a subset of genes that are
different from those regulated by p-STATs (31, 39, 42). Together these data suggest
that uStat1 may be transcriptionally active and may play a significant role in various
cellular responses. Transcriptional profiling has shown that the majority of uStat1
target genes are antiviral immune response genes, however, uStat1 also induces a
subset of genes implicated in radio- and chemo-resistance in cancer cells (42) (43).
Disruption of IFN effector molecule 8 (IRF8) in soft tissue sarcoma cells leads to the
accumulation of uStat1 (44) and promotes sarcoma cell metastasis by regulating gene
transcription of apoptosis regulators Fas and Bad (44). Overall, the role and
mechanism(s) by which uStat1 mediate cellular responses and possible protumorigenic effects are largely unknown.
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1.11 Evidence for a Pro-Tumorigenic Role of Stat1
As previously stated, Stat1 is widely considered to possess tumor suppressive
properties. There is emerging data that Stat1 may influence tumorigenesis by
modulating several different aspects of tumor development. Utilizing large-scale gene
expression studies from melanoma patients, Stat1 was shown to be elevated at the
peripheral edge (invasion front) compared to central areas of the tumor. In addition,
stable knockdown of Stat1 in metastatic melanoma cells significantly impaired their
migratory and invasive capacity in matrigel and wounding assays (45).
Stat1 may also influence tumorigenesis by suppressing the apoptotic response
although in many instances Stat1 has a pro-apoptotic function. For example,
overexpression or constitutive activation of Stat1 may provide resistance to genotoxic
stress including chemotherapy and ionizing radiation (IR). Utilizing a squamous cell
carcinoma cell line (SCC61), which was serially passaged to create a radioresistant cell
line (nu61), Khodarev et al reported that nu61 cells were unresponsive to cytotoxic
signals by radiation or IFNs, but suppression of Stat1 by short hairpen RNA rendered
nu61 cells radiosensitive to IR. They proposed a model where transient induction of
Stat1 activates cytotoxic genes, which results in cell death. Overexpression of Stat1
led to the suppression of the cytotoxic response and induced the expression of prosurvival genes (MCL-1, IFITM1, and USP18) that render the cells resistant to apoptosis
(46).
As previously stated, Stat1 may also influence tumor development by regulating
key components of the antigen presentation machinery, such as MHCI and II. Kovacic
et al found that Stat1 deficiency inhibited the development of leukemia in Stat1-/- mice
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(47). Loss of Stat1 resulted in low levels of MHC class I proteins, which apparently
enabled efficient NK cell lysis, and enhanced tumor clearance. These findings define
Stat1 as a tumor promoter in terms of leukemia development, since the upregulation of
MHC I provides a mechanism by which newly formed tumors escape elimination by
immune surveillance.
Over the years it has been suggested that Stat1 has a role in the induction of a
pro-inflammatory signaling cascade. Stat1 has been found to be associated with
several human pathological conditions associated with chronic inflammation including
rheumatoid arthritis (48), pulmonary fibrosis (49), and Alzheimer’s disease (50) . Stat1
influences the inflammatory response by inducing key components such iNOS (51) and
IRF-1 (52). Utilizing models of inflammation-associated cancers, several groups have
demonstrated the importance of Stat1 in inflammation. Stat1 was shown to provide a
pro-inflammatory signal in ConA-induced hepatitis by driving the expression of several
chemoattractant chemokines via IRF-1 (53). In addition, utilizing a model for gastric
cancer, Ernest et al reported that loss of Stat1 reduced gastric cancer associated
inflammation by reducing the pro-inflammatory interleukin, IL-11. Collectively these
findings demonstrate the complexity of Stat1 signaling, whereby Stat1 has a protumorigenic function by desensitizing cells to apoptosis, increasing metastatic potential,
decreasing host recognition capacity and increasing the pro-inflammatory program.
Table 1 summarizes Stat1 responsive genes involved in the process of tumorigenesis.
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Table 1. Summary of Stat1 responsive genes that are involved in the
process of tumorigenesis
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1.12 Multistage Epithelial Carcinogenesis in Mouse Skin
Skin carcinogenesis in mice can be accomplished by utilizing either complete or
initiation-promotion protocols (54). The complete carcinogenesis protocol involves the
topical application of a single large dose or repeated applications of a smaller dose of a
carcinogen [i.e. 7,12-Dimethylbenz(a)anthracene (DMBA), 3-methylcholanthrene
(MCA)]. The initiation-promotion protocol involves the application of a single
subcarcinogenic dose of a carcinogen followed by repeated applications of a tumor
promoter. This well-established protocol in mouse skin recapitulates many aspects of
human epithelial cancer (54). Cancer development is a complex process whereby a
normal cell undergoes genetic alterations that results in an altered phenotype that is
characterized by a selective growth advantage. Multiple lines of evidence suggest that
these alterations occur in a multi-step process (55). The complete carcinogenesis
model does not allow interpretation of different stages of the tumorigenic process,
whereas the initiation-promotion protocol allows for observable delineation. In the
initiation-promotion protocol three distinct mechanistic stages can be identified.
Initiation involves a DNA damaging event leading to mutation(s) in critical target cells
(i.e. stem cells). Promotion involves increased proliferation and altered cell behavior,
which allows for clonal expansion of initiated cells into clonal outgrowths called
papillomas. Finally, tumor progression is characterized by the conversion of papillomas
to SCCs.
The first stage in chemically induced skin carcinogenesis is referred to as
“initiation” and involves a DNA damaging event to genes in epidermal keratinocytes.
The most commonly used initiating agent is the polycyclic aromatic hydrocarbon (PAH),
DMBA. DMBA causes a specific A to T (182) transversion mutation in codon 61 of the
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Hras1 gene, although Kras mutations have also been documented in lesions initiated
with DMBA [reviewed in (54)]. Mice are treated topically with a sub-carcinogeneic dose
of DMBA that primarily targets keratinocyte stem cells, which are found at the base of
the epidermal proliferative units and in the bulge region of the hair follicle [reviewed in
(54, 56)].
During the process of tumor promotion, initiated stem cells undergo clonal
expansion. The promotion stage is characterized by repeated applications of chemical
agents called tumor promoters (e.g. TPA, chrysarobin (CHRY), okadaic acid, and
others) or wounding leading to sustained epidermal hyperplasia and epidermal
proliferation. Initiated stem cells that harbor Ras mutations are believed to have a
selective growth advantage during tumor promoter-induced epidermal proliferation.
Classical tumor promoters are not intrinsically mutagenic but alter the expression of
genes that are associated with tissue remodeling, hyperplasia, and inflammation (57).
Repeated exposure to a given tumor promoter may increase mitogenic factors,
increase inflammatory mediators and inhibit anti-apoptotic molecules. The end result of
the promotion stage is characterized by the development of pre-malignant outgrowths
in the skin called papillomas.
The progression stage of multistage carcinogenesis results in further genetic
alterations such as loss of heterozygosity, aneuploidy and trisomy leading to the
conversion of pre-malignant papillomas to malignant SCCs (54). A typical initiationpromotion protocol using DMBA and TPA leads to the robust formation of both
papillomas and SCCs. The frequency of malignant conversion is dependent on many
factors such as genetic background, dose of initiator and type of promoter used (54).
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Figure 6. Multistage Carcinogenesis in Mouse Skin. The initiation-protocol protocol
involves the application of a subcarcinogenic dose of a carcinogen (DMBA, MCA,
MNNG) followed by repeated applications of a tumor promoter (TPA, UV, CHRY,
wounding). The model is divided into three distinct mechanistic stages: initiation,
promotion and progression. The initiation phase is characterized by an irreversible DNA
damaging event in the target cells of the epidermis. The second stage, promotion,
involves repeated applications of a tumor promoter, which lead to the clonal expansion
of initiated cells. During the promotion stage, benign pre-malignant outgrowths called
papillomas develop. In the final stage, cells undergo further genetic alterations leading
to increased genomic instability. During this final stage, papillomas convert to invasive
squamous cell carcinomas (SCC). Figure adapted from Abel et al. 2009 Nature
Protocols.
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1.13 Mechanisms of Skin Tumor Promotion
While the initiation stage of mouse multi-stage skin carcinogenesis is
relatively well understood in terms of molecular mechanism, the mechanisms
underlying the promotion stage are less well defined. Tumor promotion is
characterized by the development of a dramatic increase in epidermal cell
proliferation and by significant dermal changes characterized by inflammation
(58-62). Processes altered during tumor promotion include increased DNA
synthesis, increased ODC activity, increased growth factor production, altered
redox status and increased prostaglandin synthesis [reviewed in (63)]. The
effects observed during tumor promotion are largely due to promoter-induced
alterations in gene expression and signaling molecules (58-60, 64, 65). In
general, many genes that encode growth regulatory molecules are up-regulated
(mRNA and protein) or enzymatic activities are stimulated in response to
exposure of mouse skin to tumor promoting stimuli (63, 66). A number of
changes in growth regulatory proteins and molecules occur during tumor
promotion in the mouse skin model that are thought to stimulate a cascade of cell
signaling events that alter cell proliferation and/or differentiation. Some of these
proteins/molecules include: protein kinase C (PKC), EGFR, transforming growth
factor alpha (TGF), transforming growth factor beta 1 (TGF); and
prostaglandins. Downstream mediators of these regulatory molecules include
but are not limited to: protein kinase B (AKT), c-myc proto-oncogene (MYC), FBJ
osteosarcoma oncogene (c-FOS), E2F transcription factor 1 (E2F-1),
transformation related protein 63 (p63), mitogen activated protein kinase (MAPK),
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phosphatidylinositol 3-kinase (PI3K), cyclin D1 (CCND1), and STAT3.
For the phorbol ester type tumor promoters (includes TPA, teleocidins and
aplysiatoxins) the cellular receptor that initiates their actions is PKC (67). For
compounds such as OA and calyculin A, the cellular receptors are protein
phosphatases 1 and 2A (68). For many other skin tumor promoters, the
existence of cellular receptors is not known and for compounds that break down
to form reactive oxygen species and other types of radical intermediates such as
the anthrones (e.g., anthralin, CHRY) and the organic peroxides [e.g., benzoyl
peroxide (BzPo)] it is believed that they work by inducing oxidative stress that
can activate multiple signaling pathways associated with skin tumor promotion
(69).

1,8-dihydroxy-3-methyl-9-anthrone (chrysarobin or CHRY) is a prototypical
anthrone derivative that represents a class of skin tumor promoters that work
through a mechanism that is different than the phorbol esters. CHRY does not
directly interact with the PKC receptor suggesting that its activity is independent
of the PKC signaling pathway (70). CHRY is very similar to another 9-anthrone
derivative, anthralin. Anthralin was first shown to be an effective tumor promoter
by Bock and Burns in ICR Swiss mice over 40 years ago (Bock and Burns 1963)
and subsequently CHRY was shown to be approximately 2-fold more active than
anthralin when applied at equimolar doses (71). Anthrones such as CHRY and
anthralin undergo auto-oxidation in biological fluids producing reactive oxygen
species and anthrone intermediate radicals. Utilizing electron spin resonance,
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anthralin has been shown to produce several oxidized products in mouse skin,
including singlet oxygen and superoxide anion radicals (72, 73). Structureactivity studies for tumor promoting activity with anthrone derivatives have shown
that oxidation at C10 of the molecule and subsequent generation of ROS is critical
for their tumor promoter activity (74).
Despite the known differences in mechanism between TPA and CHRY,
both compounds cause several similar histological and biochemical alterations
such as ornithine decarboxylase (ODC) induction and increased polyamine
synthesis, increased epidermal DNA synthesis, edema, and hyperplasia following
topical treatment. ODC is the rate-limiting step in the synthesis of the
polyamines. At optimal promoting doses, induction of ODC and subsequent
polyamine synthesis by CHRY exhibited differences in time course and
magnitude compared to TPA (75, 76). Epidermal DNA synthesis as well as
epidermal hyperplasia of mice skin treated topically with CHRY exhibited a
delayed peak compared to TPA (76) (77). The results from these early studies
has shown that hyperplasia produced in mice treated with TPA reached a
maximum level at 48 hrs compared to mice treated with CHRY, which peaked at
96 hrs following treatment. Collectively, these findings have suggested that
although TPA and CHRY ultimately produce similar effects (epidermal
hyperproliferation, inflammation, and tumor promotion) their initial
biochemical/molecular mechanism is different.
1.14 Role of Inflammation in Cancer and Tumor Promotion
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Calor Dolor Rubor and Tumor translates to Heat, Pain, Redness and
Swelling which represents the four classical signs of inflammation as was
originally described by the First century encyclopedist Celsus AC., (Celsus AC.,
De medicina. Self published; A.D. 25). The functional relationship between
inflammation and cancer is not new. There is overwhelming experimental and
epidemiological evidence that illustrates the importance of inflammation during
the process of cancer development (78) . Prostaglandin endoperoxide H
synthases, also known as cyclooxygenase (Cox) is a key enzyme involved in this
complex signaling cascade (79).
Cox enzymes catalyze the synthesis of prostaglandins from arachidonic
acid (AA). Cox enzymes exist in predominately two major isoforms, Cox-1 and
Cox-2. Cox-1 is constitutively expressed in most cells and is responsible for
tissue homeostasis, such as maintenance of gut mucosa and renal blood flow
[reviewed in (80) ]. Cox-2, on the other hand, is an inducible protein that exists at
low levels in mammalian cells devoid of stimulation. Cox-2 can be activated by a
variety of stimuli including bacterial endotoxins, cytokines, growth factors and
hormones. There is overwhelming evidence linking Cox-2 expression to the
development of cancer. Cox-2 has been shown to be overexpressed in various
pre-malignant and malignant tissues, such as actinic keratosis/SCCs,
adenoma/adenocarcinoma and bile duct hyperplasia/cholangiocarcinoma,
[reviewed in (78)].
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There are also several lines of experimental data that support the role of
Cox-2 in the process of tumorigenesis. Female transgenic mice that overexpress
Cox-2 in mammary tissue developed focal mammary gland hyperplasia,
dysplasia and metastatic tumors (81). Lastly, in addition to data from
epidemiological and genetic studies, there are also numerous pharmacological
studies that indicate that Cox-2 is a suitable therapeutic target. Treatment with a
selective Cox-2 inhibitor reduces the formation of tumors in inflammationassociated malignancies such as intestinal (82), colon (83), bladder (84) , and
skin tumors (85) in animals.

Growth factors, cytokines and tumor promoters stimulate Cox-2 expression
by multiple signaling pathways including PKC and Ras-mediated signaling
[reviewed in (78)]. Tumor promoters such as UV and TPA are known to induce
Cox-2 expression in epidermis following exposure (86, 87). It has been shown
that both Cox isoforms have a role in keratinocyte differentiation. Utilizing the
two-stage skin model, it was reported that tumor development in Cox-1 and Cox2 null mice were reduced compared to wild-type mice and was associated with
premature keratinocyte differentiation (88). Further studies have revealed that
the impact of Cox-2 on epithelial tumorigenesis is context dependent.
Transgenic mice that overexpress Cox-2 under the control of the keratin 14
promoter (K14), referred to as K14.Cox-2 mice, were shown to be resistant to
skin tumor formation using the two-stage model when TPA was used as the
promoting agent. The decrease in tumor development was attributed to reduced
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ODC induction, reduced interleukin-1α, and reduced TNFα in these K14.Cox-2
mice. In the same study, it was also shown that K14.Cox-2 transgenic mice
when promoted with anthralin developed 6 times more tumors than control mice.
Additionally, K14.Cox-2 mice treated only with DMBA developed 3.5 times more
tumors compared to wild-type control mice (89). Collectively, these results
demonstrated the Cox-2 expression was important for epithelial tumor
development and its role is context dependent.

The biological effects of Cox-2 induction are largely mediated via the
actions of a class of signaling molecules called prostaglandins (PGs).
Prostaglandins have several different isoforms that include PGE2, PGD2, PGI2,
and PGF2. PGE2 represents the most abundant isoform produced in the skin.
PGE2 induces keratinocyte proliferation via multiple pathways including EGFR
and PI3K (90). PGs bind to four G-protein linked membrane receptors referred to
EP1, EP2, EP3, and EP4 (91). Mouse epidermis treated with TPA increase EP1
and EP2 expression and both are upregulated in DMBA/TPA-induced papillomas
and carcinomas (92). Taken together these findings suggest Cox-2 expression
and subsequent PGE2 induction are important signaling events in epithelial
tumorigenesis.
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Chapter 2: Rationale, Hypothesis and Specific Aims
Rationale
The primary goal of this research project is to understand the role of Stat1
in multistage epithelial carcinogenesis and tumor promotion using the multistage
mouse skin model. Aberrant activation of STAT signaling has been associated
with various pathological events, including cellular transformation and
oncogenesis. Of all the STAT family members Stat1, 3 and 5 are most commonly
associated with cell growth, proliferation, and apoptosis in cancer. Previous work
performed in our laboratory has established a critical role for Stat3 in epithelial
tumorigenesis. However, the role of Stat1 in epithelial tumorigenesis has not
been well defined. Traditionally, Stat1 activity has been most commonly
associated with anti-tumorigenic properties through modulating key components
of immune tumor surveillance, inducing pro-apoptotic regulators such as
Fas/FasL, caspases, and regulating cell cycle regulating genes as p21 and p27.
Stat1 is also considered an indispensible upstream regulator of interferon
signaling, as Stat1 deficient cells are unresponsive to both Type I and Type II
interferons. The overall contribution of the IFNγ/Stat1 axis to the tumorigenic
process is poorly understood and recent evidence suggests a pro-tumorigenic
role for this pathway in several cancers.
Recently, we have found that Stat1 is absolutely required for skin tumor
promotion by the non-phorbol ester tumor promoter, CHRY, but not for tumor
promotion by the classical phorbol ester tumor promoter, TPA. This requirement
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for Stat1 in tumor promotion by CHRY involves IFNγ signaling and the induction
of IRF-1 and unphosphorylated Stat1 (uStat1) in the epidermis.

Hypothesis
The hypothesis to be tested is that Stat1 plays a critical role in skin tumor
promotion by CHRY but not TPA. An additional hypothesis to be tested is
that activation of Stat1 by CHRY occurs via IFNγγ signaling.
Specific Aims
Specific Aim 1: To determine the effect of treatment with mechanistically
distinct tumor promoters on Stat1 activation in mouse epidermis. In this
aim, we evaluated STAT1 activation following treatment with diverse tumor
promoting agents in dorsal mouse skin.

Utilizing Western blot analysis, we

evaluated the activation status of Stat1 proteins following treatment with single
and multiple applications of mechanistically distinct tumor promoters.
Specific Aim 2: To determine the effect of Stat1 deficiency on epithelial
tumorigenesis and investigate the underlying mechanism of CHRYmediated tumor promotion. Utilizing the two-stage skin carcinogenesis model,
we evaluated the impact of Stat1 deficiency on epithelial tumorigenesis using
both TPA and CHRY. In addition, we evaluated the impact of Stat1 deletion on
short-term markers of tumorigenesis such as the proliferative response,
apoptosis and differentiation.
Specific Aim 3: To determine the role of IFNγγ signaling in activation and upregulation of Stat1. In this aim, we investigated the IFNγ/Stat1/IRF-1 signaling
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axis following multiple treatments with either TPA or CHRY. In addition, utilizing
loss of function mouse models we also investigated the impact of Stat1 and
IFNγR loss on interferon-mediated signaling following treatment with both CHRY
and TPA.
Specific Aim 4: To determine the role of IFNγγ/pStat1/IRF-1 signaling on
inflammatory signaling induced by CHRY. In this aim, we examined the
impact of Stat1 deficiency on both TPA- and CHRY-mediated Cox-2 expression.
The status of several other signaling pathways following topical application of
either TPA or CHRY in both wild-type and Stat1 deficient (Stat1-/-) mice were also
investigated. Utilizing Western blot and qPCR analysis, we evaluated the
inflammatory response following treatment with both TPA and CHRY.
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Chapter 3: Materials and Methods
Animals, Antibodies, Chemicals and Reagents
Animals
Stat1-/- mice were a generous gift from Dr. David Levy (Kaplan Cancer Center,
New York School of Medicine, New York, NY). A functionally null Stat1 allele
was generated by deleting a portion of the protein-coding region. Using genetargeting techniques, 5.7 kb of genomic DNA was deleted. The DNA that was
excised contained three complete exons and a portion of a fourth that encode
amino acids 221-365. The deletion results in the loss of a portion of the DNAbinding Domain (DBD), which produces a functionally inert protein (93). Stat1-/knockout progeny were born at the expected frequencies from heterozygous
mating, and exhibited no gross developmental abnormalities described by Durbin
et al (93). Even though Stat1 mice developed normally they were extremely
sensitive to microbial challenge, (93, 94). Stat1-/- mice were originally generated
on a mixed C57Bl/6 genetic background. These mice were backcrossed for 5
generations onto the FVB/N background. Heterozygous (Stat+/-) mice were then
mated to generate Stat1-/- and Stat1+/+ littermate control mice. IFNγR1 deficient
(IFNγR1-/- ) mice were purchased from The Jackson Laboratory (Bay Harbor, MA)
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Antibodies and Reagents
Polyclonal rabbit anti-Cox-2 was purchased form Cayman Chemical Co.
(Ann Arbor, MI); Rabbit anti-IRF-1 from Santa Cruz Biotechnology (Santa Cruz,
CA) and Antibodies against phoshpo-Stat1 Y701, phospho-Stat1 S727 and total
Stat1 were purchased Cell Signaling Technologies (Danvers, MA).
Chemiluminescence detection kits were purchased from Pierce (Rockford, IL). 7,
12 dimethylbenz(a)anthracene (DMBA), 5-bromo 2-deoxyuridine (Brdu), protease
inhibitor cocktails, phosphatase inhibitor cocktails, mouse and rabbit secondary
antibodies, and beta-actin were purchased form Sigma-Aldrich (St. Louis, MO).
12-O-Tetradecanoylphorbol 13-acetate (TPA) was purchased from Alexis
Biochemicals (Plymouth Meeting, PA). Chrysarobin was synthesized in house
from chrysaphanic acid as previously described (95).. Mouse recombinant
interferon gamma rIFNγwas purchased from BD Bioscience and used at 250
ng/ml in primary cultures as previously described(96).

Short-term promotion experiments
For experiments were only Stat1 wild-type mice were used, female FVB/N
mice (7-9 weeks of age) were purchased from the National Cancer Institute
(Fredrick, MD) and group housed for the duration of the study in all experiments.
In all other instances, Stat1-/- and Stat1+/+ mice were obtained from in house
breeders as described above. The dorsal skin was shaved 48 hrs prior to
treatment with the indicated tumor promoter. Mice were treated with either
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acetone vehicle (0.2 ml), TPA (3.4, 6.8, 13.6nmol) twice weekly for two weeks or
with chrysarobin (100, 220, 440 nmol) once weekly for four weeks. Mice were
sacrificed at the indicated time point(s) following the last treatment.
For the analysis of epidermal proliferation and thickness, mice were
injected intraperitoneal (i.p.) with 5-bromo-2'-deoxyuridine (BrdU) in PBS (100
µg/g body weight) 30 min. prior to sacrifice. Excised dorsal skin sections were
fixed in 10% neutral buffered formalin for 24-48 hrs and embedded in paraffin.
Sections were either stained with, S100A8, K1, K5, K10, loricrin, K6, Hemotoxylin
and eosin (H&E), anti-BrdU antibody or anti-caspase-3 by the histopathology
core at UT MD Anderson Cancer Center-Smithville Science Park Division.
Epidermal index was calculated as the percentage of BrdU positive cells; 600
basal cells were counted from 3-4 skin sections for each mouse. For epidermal
thickness, 20 measurements were taken for each of 3-4 skin sections per mouse
and the average thickness was calculated (97). Apoptotic keratinocytes were
counted microscopically and the index was calculated from the total number of
caspase-3 positive basal cells in the entire skin sections from 3-4 individual mice
from each group.

Two-Stage Skin Carcinogenesis model
Groups of 15-29 Stat1+/+ and Stat1-/- age matched females were used per
group. Forty-eight hours prior to initiation the dorsal skin of was shaved. Mice
were initiated with 25nmol DMBA dissolved in 0.2ml acetone. Two-weeks after
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initiation mice received topical application of specified tumor promoter. Due to
mechanistic differences we used two different treatment regiments for promotion
with TPA and CHRY. Two weeks after initiation, mice were treated topically with
either 0.2ml acetone, 6.8nmol TPA, or 220nmol CHRY in 0.2 ml acetone. Mice
were treated twice weekly with TPA or treated once weekly with CHRY. Mice
received tumor promoter treatments until tumor multiplicity plateaued. Tumor
incidence (percentage of mice with papilloma) and tumor multiplicity (average
number papilloma per mouse) was recorded weekly for the duration of the
studies.

Epidermal Lysate preparation
After euthanization, the depilatory agent Nair was applied to the dorsal
skin of mice for 30-45 sec and removed under running water. The skin was then
excised and the epidermal layer was removed by scraping with a razor blade into
chilled lysis buffer (1M Tris HCL pH 7.4, 3M NaCl, 0.5M EDTA pH 8.0, 10%
Triton X-100, protease inhibitor, phosphatase inhibitor cocktail 1 and 2) and then
homogenized using an 18-gauge needle. Epidermal lysates were centrifuged at
14,000 RPM for 15min, and supernatant was collected. Protein concentration
was determined and supernatant was snap frozen using liquid nitrogen and
stored at -80°C until further analysis.
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Adult Primary Keratinocyte Culture
Primary mouse keratinocytes were isolated from 6-8 week old Stat1 wildtype and Stat1-/- mice as previously described (98). Briefly, mice were shaved,
treated with a hair depilatory agent, after which dorsal skin was excised and
floated on 0.25% trypsin for 4 hrs. The epidermal cell layer was separated from
dermis, minced and stirred in growth media supplemented with 10% fetal bovine
serum for 30 min. The cell suspension was filtered through a 70 m cell strainer.
Cells were counted using a hemocytometer and plated on collagen coated plates
and maintained in complete keratinocytes growth medium made up of Eagle's
minimal essential base medium without Ca2+ supplemented as previously
described (98). Primary keratinoctyes were serum starved for 24 hrs prior to
treatment.

Western Blot Analysis
Protein concentration was determined using Lowry protein assay
according to manufacturer instructions. Fifty micrograms of protein lysate per
lane was electrophoresed in 4-15% SDS-Page gradient gels and then transferred
onto 0.45 um nitrocellulose membranes (BioRad, Hercules, CA). Membranes
were blocked for 1 hour in 5% bovine serum albumin (BSA) in TBS with 0.1%
tween (TBST) and incubated overnight at 4°C with specified primary antibody.
The membranes were washed 3 times for 15 min each in TBST. Membranes
were then incubated for 45 min in corresponding horseradish peroxidase-
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conjugated secondary antibodies in 3% non-fat dry milk (NFDM). Membranes
were then washed 3 times for 15 min. Protein bands were visualized using a
chemiluminescence detection kit (Pierce ECL Western Blotting Substrate,
Rockford, IL). Quantitation of total protein, and relative phosphorylation levels
were calculated by densitometric analysis. Actin was used to normalize protein
loading and relative phosphorylation is calculated as a percentage of total protein.

mRNA analysis by Real-Time PCR.
Epidermal scrapings from the dorsal skin of sacrificed mice was submerge
into RNA Later and placed at 4C for a minimal of 48 hrs. Total RNA was isolated
by using the QIAGEN RNeasy RNA Isolation kits (74104) according to
manufactures instructions. First strand cDNA synthesis kit using random
hexamer primers (Invitrogen) was used for cDNA preparation. SYBR Green was
used for quantitative real-time PCR, which was performed on the Applied
Biosystems RT-PCR system (Applied Biosystems Viia 7). Relative gene
induction was calculated using Viia 7 software using the comparative Ct method
(∆∆CT).

Quantitation of Cytokines and Chemokines
RT2 Profiler PCR array mouse inflammatory cytokines and receptors
(PAMN-011Z) (n = 4) were used to analyze the expression of a focused panel of
genes. Data analysis was performed using the ∆∆CT method according to the
manufacturer’s protocol (SABiosciences).
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Prostaglandin E2 Assay
Dorsal epidermis was chipped from frozen skin into ice-cold Eicosanoid
Affinity Column Buffer (0.5 M phosphate solution, pH 7.0, containing 2.5 M
sodium chloride and 0.25% sodium azide) containing 10 µmol indomethacin.
After homogenization sample was centrifuged at 8,000X g for 10 min.
Supernatant was collected. Samples of mouse origin may contain antibodies,
which interfere with the assay by binding to the goat anti-mouse plate. Samples
were purified prior to assay. PGE2 was purified by passing clear supernatant
through prostaglandin E2 affinity columns (Caymen chemical), the eluate was
dried under a steady stream of nitrogen. For assay, PGE2 was reconstituted in
enzyme immunoassay (EIA) buffer (Cayman Chemical Company, Ann Arbor, MI)
and assayed according to the manufacturer’s instruction.

Statistical Analyses.
To compare epidermal thickness (µm) and labeling index (LI) (% BrdU
positive cells) data were presented as the mean ± standard error of the mean
(SEM). For comparisons of epidermal thickness and LI, the Mann- Whitney Utest was used (significance set at p≤0.05). For comparison of tumor incidence
the Chi-square (χ2) test was used (significance set at p≤0.05). For comparison
of tumor multiplicity data, the Mann-Whitney U-test was used (significance set at
p≤0.05). Statistical analysis was conducted using GraphPad Prism 4 software
(San Diego, CA).
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Antibody List
Antibody
Phospho-Stat1(Tyr701)
Phospho-Stat1 (Ser727)
Stat1
Phospho-NF-κB (Ser536)
NF-κB
IRF-1
Actin
K5
K10
K1
Loricrin
K6
Cox-2

Gene
Cox-2
IRF-1
IFNα
IFNβ
IFNγ
Stat1
GAPDH

Vender
Cell signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Santa Cruz
Sigma Aldrich
Covance
Covance
Covance
Covance
Covance
Caymen

Forward Primer sequence
CAAGACAGATCATAAGCGAGGA
AATTCCAACCAAATCCCAGG
TCCCTGTGCTGCGAGATCTTACTC
ACACTGCCTTTGCCATCCAAGAG
CGAGATGACTTCGAAAAGCTG
TCCCGTACAGATGTCCATGAT
TGTTCCAGAGACGGCCGCATCTTC

Catalog number
9171
9177
9172
3033
8242
Sc-640
A2066
PRB-160P
MMS-159S
PRB-165P
PRB-145P
PRB-169P
160126

Reverse Primer sequence
GGCGCAGTTTATGTTGTCTGT
AGGCATCCTTGTTGATGTCC
CTGCTGCATCAGACAGGTTTGC
TCCACCCAGTGCTGGAGAAATTG
TCAGCCATCACTTGGATGAG
CTGAATATTTCCCTCCTGGG
AATGGCAGCCCTGGTGACCAGGC
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Chapter 4: Effect of treatment with mechanistically distinct tumor promoters on
Stat1 activation in mouse epidermis
Rationale
As stated in the introduction, STAT activation proceeds by a process of
phosphorylation on conserved tyrosine and serine residues. Phosphorylation of these
conserved residues is critical for STAT transcriptional activity, but accumulating data
has established a mechanism whereby uSTATs may also affect gene expression and
contribute to the overall effects associated with this transcription factor. In previous
studies, it was shown that a variety of tumor promoters including the commonly used
phorbol ester TPA, the phosphatase inhibitor okadaic acid, and the anthrone derivative
CHRY activated epidermal STATs, following topical treatment. All these tumor
promoters were found to activate Stat3 in epidermis and in addition TPA was found to
activate Stat1 and Stat5 (99). The aim of this project was to further expand our
knowledge of Stat1 activity/phosphorylation following treatment with various tumor
promoters. By utilizing mechanistically distinct tumor promoters the goal was to
determine whether activation of Stat1 was a common mechanism in tumor promotion.

4.1 Effect of a single topical application of mechanistically distinct tumor
promoters on Stat1 activation in epidermis
For these experiments, groups of 3-4 female FVB mice (6-8 weeks of age)
received a single topical application with either acetone vehicle or 6.8 nmol TPA, 7.5
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nmol okadaic acid or 220 nmol CHRY. Mice were sacrificed at the indicated time
points and epidermal lysates were prepared as previously described. As shown in
Figure 7, topical application of TPA caused an increase in Stat1 phosphorylation. In
this regard, following TPA treatment there was a significant increase in serine 727
(S727) phosphorylation as early as 3 hrs, and phosphorylation remained elevated for at
least 18 hrs following treatment. Tyrosine phosphorylation of Stat1 was observed to be
slightly elevated at 6 hrs following treatment. TPA treatment also resulted in an
approximate 1.5 fold increase of total Stat1 protein 18 hours following treatment.
Topical treatment with CHRY also led to an increase in phosphorylation of Stat1 on
both tyrosine and serine residues compared to the acetone control group. In addition,
CHRY treatment also led to an approximate 2-fold increase in total Stat1 as early as 18
hrs following treatment. At the time points evaluated, there were no significant changes
in Stat1 phosphorylation compared to the acetone controls following okadaic acid
treatment. These data suggested that activation/phosphorylation represents an early
signaling event following topical treatment with both TPA and CHRY. The increased
tyrosine phosphorylation of Stat1 following both TPA and CHRY appeared to be due
primarily to increases in Stat1 protein. The increased phosphorylation of Stat1 on S727
by CHRY also appeared to be due to increased Stat1 protein whereas TPA treatment
led to a significant increased phosphorylation at S727 (see quantitation in Figure 7).
Because the process of tumor promotion involves repeated treatments with tumor
promoters, the next set of experiments involved using a multiple treatment regimen
using both TPA and CHRY.
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Figure 7. Effect of a single topical application of TPA, CHRY, and okadaic acid
on epidermal Stat1. FVB mice (3-4/group) received a single topical application of
either 6.8 nmol TPA, 7.5 nmol okadaic acid (OA), or 220 nmol CHRY in 0.2 ml
acetone (Ace) and were sacrificed at the indicated timepoints. A) Mice were
sacrificed at various time points and epidermal protein lysates were prepared for
Western blot analysis using antibodies specific for the indicated proteins. B)
Quantitation of total protein, normalized phospho-Stat1(S727) and normalized
phospho-Stat1(Y701) were determined by densitometric analysis. Actin was used to
normalize protein loading and normalized phosphorylation is calculated as a
percentage of total protein. Values represent the average of three experiments ±
SEM.
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4.2 Effect of Multiple treatments with TPA and CHRY on Epidermal Stat1
To better understand Stat1 signaling following tumor promoter treatment,
we used a multiple treatment regimen for both TPA and CHRY and established a
time course for Stat1 activation/phosphorylation. Stat1-/- mice and wild-type
controls were treated topically using a multiple treatment regimen involving 4
treatments with either acetone, 6.8nmol TPA (2x/week for two weeks) or
220nmol CHRY (1x/week for four weeks). Mice were sacrificed at the specified
time points and epidermal lysates were prepared for protein analysis by Western
blot.
As shown in Figure 8, topical application with both TPA and CHRY induced
rapid phosphorylation of epidermal Stat1 on both tyrosine (Y701) and serine
(S727). In this regard, phosphorylation at both Y701 and S727 occurred as
early as 6 hrs following the last treatment with either promoter. Phosphorylation
at S727 persisted for up to 24-48 hrs after treatment whereas phosphorylation at
Y701 was more transient. During the course of these experiments, we observed
that Stat1 protein levels were consistently increased at later time points following
treatment with CHRY but not TPA (see again Figure 8) with a peak occurring
approximately 48 hrs after treatment. This increase in Stat1 protein level
occurred at a time when little or no phosphorylation could be detected. Thus,
CHRY treatment led to the induction of uStat1. To determine the mechanism for
increased uStat1, we measured epidermal Stat1 mRNA levels following a single
application of CHRY. As shown in Figure 9, CHRY treatment led to a significant
increase in Stat1 mRNA. Thus, the increase in uStat1 protein was due to an
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increase in Stat1 mRNA. As shown if Figure 9, Stat1 mRNA levels increased as
early as 6 hrs (the earliest time point examined) and reached peak levels at 12
hrs before returning to basal levels 24 hrs after treatment. Collectively, the data
in Figures 8 and 9, demonstrate that treatment with both tumor promoters led to
rapid activation of Stat1 (i.e. phosphorylation on both tyrosine and serine
residues). However, only CHRY led to induction of uStat1.
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Figure 8. Effect of multiple topical applications with TPA and CHRY Stat1 on
phosphorylation/activation. Stat1 wild-type (Stat1+/+) or Stat1 Knock-out (Stat1-/-)
mice received four topical applications of either 6.8 nmol TPA, or 220nmol CHRY in
0.2 ml acetone (Ace). Epidermal lysates were collected for protein analysis by
Western blot. Mice were sacrificed at the indicated timepoints following last
treatment and probed using antibodies specific for indicated protein. Quantitation of
total protein levels was assessed by densitometric analysis. Actin was used to
normalize protein loading. A) Western blot analysis of Stat1 following topical
application of TPA; B) Western blot analysis of Stat1 following topical application of
CHRY.
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Figure 9. A single application of CHRY led to de novo synthesis of
Stat1 mRNA. Wild-type (FVB) mice 6-8 weeks of age, received a single
topical application of 220 nmol CHRY. Mice were sacrificed at the
indicated time points for analysis of mRNA expression of Stat1 by RTPCR. * Represents significant differences from acetone control (Pvalue ≤ 0.05)
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4.3 uStat1 is elevated and detected in nuclei of epidermal keratinocytes
As previously stated in the Introduction, STATs undergo cycles of
cytoplasmic-nuclear shuttling. Although uSTATs have been reported to shuttle
between the nucleus and cytoplasm in un-stimulated cells the general consensus
remains that STAT molecules require tyrosine phosphorylation for nuclear
localization to induce subsequent gene expression (100). Accumulating data has
established a role for unphosphorylated STATs at the transcriptional level (39, 40,
43). To investigate whether uStat1 could affect transcription, we evaluated
uStat1 nuclear localization. As shown in Figure 10, uStat1 was elevated in
epidermis as assessed by immunostaining at 48 hrs following treatment with
CHRY. Some nuclei appeared to be stained for uStat1. Additional confocal
microscopic analysis (Figure 11) revealed that following multiple applications of
CHRY, uStat1 could be detected in the nuclei of keratinocytes 48 hrs after the
last treatment. It should be noted that there was no detectable phosphorylation
of Stat1 at this time point (see again Figure 8). These data confirm that CHRY
treatment leads to upregulation of uStat1 and that uStat1 may have a function in
regulating gene expression as has been recently proposed (39, 40, 42).
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Figure 10. IHC analysis of Stat1 in mouse skin of Stat1wild-type and
Stat1deficient mice following multiple treatments with CHRY. Female
FVB (3-4mice/group ) mice were treated with either acetone or 440nmol
CHRY once weekly for four weeks and sacrificed 48hrs following final
treatment. Skin sections were fixed in formalin, paraffin embedded, and
immunostained for Stat1 alpha.
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Figure 11. Multiple applications of CHRY led to an increase in uStat1
nuclear localization 48hrs after treatment. Wild-type FVB mice received
either acetone vehicle or 220nmol CHRY in 0.2 ml acetone (once weekly for
four weeks). Whole skin sections were excised, fixed in formalin and paraffin
embedded. Skin sections were immunostained with Stat1 and observed using
confocal microscopy.
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4.4 Topical application of α-Tocopherol acetate (α
αTA), inhibits epidermal
proliferation and Stat1 Y701 phosphorylation by CHRY
As noted in the Introduction, anthrones such as CHRY undergo autooxidation to generate free radicals that are involved in their tumor promoting
action. Early studies from Fushs et al reported that treatment with the antioxidant
α-tocopherol acetate (α-TA) inhibited ODC induction by anthralin, (72). In early
studies performed in our laboratory, it was shown that α-TA could partially block
the effect of CHRY on EGF binding in vitro (101). In addition, early studies by
Battalora and DiGiovanni, (102) also showed that topical application of α-TA
effectively inhibited CHRY mediated ODC induction, hyperplasia and tumor
promotion. The aim of this study was to evaluate the impact of α-TA on the
epidermal proliferative response following treatment with CHRY and to evaluate
its effect on CHRY-induced Stat1 Y701 phosphorylation. For these experiments
groups, of 3-4 female FVB mice received topical application of either acetone
(vehicle), α-TA only, CHRY only or α-TA plus CHRY. Antioxidant treatment was
administered topically 5 min prior to receiving a topical dose of 220 nmol CHRY.
α-TA treatment resulted in a decrease in the proliferative response as
measured by both BrdU incorporation and epidermal thickness (Figure 12).
Mouse skin pre-treated with 10 and 40 µmol of α-TA exhibited an approximate
22% reduction in epidermal thickness compared to the CHRY treated group (46.4
microns CHRY treated group versus 35.75 microns for both does of α-TA)
(Figure 12). α-TA treatment also led to a statistically significant reduction in
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epidermal labeling index (LI) induced by CHRY (Figure 13). Compared to the
CHRY treated group, α-TA pretreatment resulted in an approximately 29% and
23% decrease for 10 and 40 µmol, respectively (20.77% labeled in the CHRY
treated group versus 14.74% and 15.94, respectively)(Figure 13).
As shown in Figure 14, α-TA pretreatment reduced total Stat1 protein
levels at 18 hrs after treatment with CHRY. In this regard, α-TA pretreatment
resulted in an approximate 1.6 and 1.3-fold (10 and 40 µmol) decrease in total
Stat1 induction compared to the CHRY only treated group. α-TA also caused an
approximate 1.8 and 4.2-fold decrease in Y701 phosphorylation compared to the
CHRY only treated group, at the 10 µmol and 40 µmol doses, respectively. After
normalization, α-TA effectively inhibited CHRY-mediated Stat1 Y701
phosphorylation by decreasing Stat1 activation 3.0 and 8.3-fold (10 µmol and 40
µmol doses, respectively) compared to the CHRY only treated group (see again
Figure 14). Collectively, these data indicate that the activation of Stat1 Y701
phosphorylation requires the generation of free radicals from CHRY.
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Figure 12. Topical application of α-tocopherol caused a significant
reduction in epidermal thickness. FVB mice (3-4/group) received a topical
application of either acetone, α-TA only, or α-TA 5 min prior to receiving an
application of 220 nmol CHRY in 0.2 ml acetone. Mice were treated once weekly
for four weeks and sacrificed 18 hrs following final treatment. Representative
sections of whole skin were stained with hematoxylin are shown.
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Figure 13. Topical application of α-TA caused a significant reduction in
BrdU incorporation. FVB mice (3-4/group) received a topical application of
either acetone, α-TA only, or α-TA 5 min prior to receiving an application of 220
nmol CHRY in 0.2 ml acetone. Mice were treated once weekly for four weeks
and sacrificed 18 hrs following final treatment. Representative sections of whole
skin were stained with 5-bromo-2-deoxyuridine (Brdu) are shown.
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Figure 14. Topical application of α-tocopherol caused a significant
reduction in Stat1 Y701 phosphorylation. FVB mice (3-4/group) received a
topical application of either acetone, α-TA only, or α-TA 5 min. prior to
receiving an application of 220 nmol CHRY in 0.2 ml acetone. Mice were
sacrificed at 18 hrs after the last treatment with CHRY and epidermal protein
lysates were prepared for Western blot analysis using antibodies specific for
the indicated proteins Normalization performed by densitometric analysis.
Actin was used to normalize protein loading and relative phosphorylation is
calculated as a percentage of total protein.
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Chapter 5: Stat1 is critical for CHRY Skin Tumor Promotion
Rationale
STATs are involved in many normal physiological processes but their aberrant
activation has been associated with many pathological conditions including
oncogenesis. Previous work performed in our lab, demonstrated that Stat1
phosphorylation was induced by TPA and was elevated in DMBA/TPA-induced
papillomas compared to control skin, (99). Furthermore, the data in Figures 8-11
suggested the possibility that activated Stat1, including uStat1 may play a important
role in skin tumor promotion by CHRY and that activated Stat1 may play a important
role in skin tumor promotion by TPA. To further explore this possibility, Stat1-/- mice
(93) were used to evaluate their susceptibility to skin tumor promotion by both TPA and
CHRY.
5.1 Impact of Stat1 deletion on susceptibility to skin tumor promotion by TPA
and CHRY
To evaluate the impact of Stat1 deletion on skin tumor promotion by TPA and
CHRY, groups of 19-29 mice for each genotype were used for two-stage skin
carcinogenesis studies. The dorsal skin of mice was shaved 48 hours prior to initiation
with DMBA. All mice received topical application of 25 nmol of DMBA in 0.2 ml acetone
to the shaved dorsal skin. Two weeks after initiation, mice were treated topically with
either 6.8 nmol TPA twice/weekly or 220 nmol CHRY once /weekly in 0.2 ml acetone.
Mice were treated topically until tumor multiplicity reached a plateau. The incidence of
papillomas (percentage of mice with papillomas) and papilloma multiplicity (average
number of papillomas per mouse) were tabulated and recorded weekly until the
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papilloma response reached a plateau. SCCs (both incidence and number) were
recorded beginning at the time the first SCC appeared. As shown in Figure 15, Stat1
deficiency had no significant effect on skin tumor development when TPA was used as
the promoting agent. In this regard, there was no significant difference in formation of
papillomas or SCCs in Stat1 deficient mice compared to wild-type controls. By week
23, Stat1 deficient mice had developed an average of 13.14 papillomas/mouse
compared to 15.25 papillomas/mouse in the wild-type control group. In addition, there
were no observed differences in tumor latency between the two genotypes. Both Stat1
deficient mice and wild-type control mice reached 100% tumor incidence by week 10.
Furthermore, there were no statistically significant differences observed in the
malignant conversion between the two genotypes (Figure 15).

In contrast to the results with TPA, mice deficient in Stat1, where highly resistant
to papilloma development when CHRY was used as the promoting agent. Stat1
deficient mice developed far fewer papillomas compared to wild-type controls (Figure
16). By week 31, Stat1 deficient mice had only developed an average of only 0.16
papillomas/mouse compared to 4.52 papillomas/mouse in the wild-type control group.
Additionally, Stat1 deficient mice reached approximately 17% tumor incidence
compared to 89% incidence in the wild-type control group. At the time of study
termination, the papillomas that developed in Stat1 deficient mice had not converted to
squamous cell carcinomas, while Stat1 wild-type mice had 0.7 SCCs per mouse and an
SCC incidence of 79%. All SCCs were confirmed histologically in mice treated with
both TPA and CHRY. Due to the unusual findings with CHRY, a repeat two-stage skin
carcinogenesis experiment was performed using groups of Stat1-/- (n=15) and wild-type
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mice (n=19). In this experiment, Stat1-/- mice again were highly resistant to skin tumor
development with CHRY. In this second experiment, wild-type mice had developed an
average of 2.5 papillomas/mouse compared to 0.14 papillomas/mouse in the Stat1-/group by week 29. In addition, Stat1 wild-type mice had reached approximately 83%
tumor incidence compared to 7.14% in the Stat1-/- group).
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Figure 15. Stat1 deficiency had no significant effect on tumor incidence and tumor
multiplicity in the two-stage skin carcinogenesis model when TPA was used as the
promoting agent. Groups of mice of each genotype, (Stat1+/+or Stat1-/-) were initiated with 25
nmol DMBA; two weeks after initiation mice were treated topically with 6.8nmol TPA twice per
week until the tumor response reached a plateau; wild-type mice (n=29): Stat1-/- mice (n=24).
A) Papilloma multiplicity and incidence B) Carcinoma multiplicity and incidence. Significant
differences in tumor incidence between groups were analyzed by Chi-square (χ2) and tumor
multiplicity was analyzed by Mann-Whitney U. *(p < 0.05, Mann Whitney U).
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Figure 16. Stat1 deficiency resulted in a significant reduction in tumor incidence
and tumor multiplicity in the two-stage skin carcinogenesis model when CHRY
was used as the promoting agent. Groups of mice of each genotype, (Stat1+/+or
Stat1-/-) were initiated with 25 nmol DMBA; two weeks after initiation mice were treated
topically with 6.8 with 220 nmol CHRY once per week until the tumor response reached
a plateau. ; wild-type mice (n=24): Stat1-/- mice (n=19). A) Papilloma multiplicity and
incidence B) Carcinoma multiplicity and incidence. Significant differences in tumor
incidence between groups were analyzed by Chi-square (χ2) and tumor multiplicity was
analyzed by Mann-Whitney U. *(p < 0.05, Mann Whitney U).
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5.2 Impact of Stat1 deletion on DMBA-induced epidermal apoptosis

To determine the impact of Stat1 deletion on epidermal apoptosis following
treatment with DMBA, Stat1-/- mice and wild-type controls were treated with DMBA and
the apoptotic response was evaluated by examining epidermal caspase-3 staining.
Groups of 3-4 wild-type control and Stat1-/- mice were treated once topically with
acetone vehicle or DMBA (200 nmol and 1000 nmol). The apoptotic response was
assessed by caspase-3 activation as described in the “Material and Methods” section.
Topical application of DMBA resulted in an increase in caspase-3 positive cells in the
epidermis compared to the acetone control, but there were no observable differences
between the response in Stat1-/- mice and the wild-type control mice at either dose of
DMBA (Figure 17). These results confirmed that Stat1 does not play a significant role
in survival of DNA damaged cells or apoptosis during initiation with DMBA. These data
also confirm that Stat1 plays a major role in tumor promotion by CHRY as indicated by
the data in Figures 15 and 16.
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Figure 17. Stat1 deficiency had no effect on epidermal apoptosis induced
by DMBA. FVB mice (3-4 mice/group) 6-9 weeks of age received a single
application of acetone, 200 nmol, or 1000 nmol of DMBA. Mice were sacrificed
48hrs following treatment. Skin sections were collected and fixed in formalin and
embedded in paraffin. Whole skin sections were stained with anti-caspase-3 and
caspase-3 positive cells were accessed.
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5.3 Impact of Stat1 deletion on epidermal hyperproliferation induced by TPA and
CHRY
Earlier studies have established a good correlation between the tumor promoting
ability of a compound with the induction of short term biomarkers such as induction of
ODC, increase polyamine synthesis, inflammation and the ability to induce sustained
epidermal hyperplasia (103). To further explore the mechanism for the dramatic
differences in response of Stat-/- mice to TPA vs CHRY, we examined the impact of
Stat1 deficiency on epidermal hyperplasia by evaluating the proliferative response as
measured by BrdU incorporation and epidermal thickness. The proliferative response
was evaluated after treatment with both tumor promoters. Mice were again treated
using a multiple treatment regimen and sacrificed 48 hrs following the last treatment.
Epidermal thickness and LI were determined as previously described in the “Materials
and Methods” section. Stat1-/- and wild-type control mice were treated with either
acetone vehicle or 3.4, 6.8, and 13.6 nmol TPA. Following TPA treatment, there were
no significant differences in BrdU incorporation or epidermal thickness at all doses
tested between Stat1-/- and wild-type control mice. Figure 18 shows representative
H&E and BrdU stained skin sections from TPA treated mice as well as quantitation of
epidermal thickness and LI at all TPA doses tested.

A parallel study was conducted to evaluate the proliferative response following
CHRY treatment. Stat1 -/- and wild-type control mice were treated with either acetone
vehicle or 110, 220, or 440 nmol CHRY using a multiple treatment regimen. Histological
evaluation showed that Stat1-/- mice treated with CHRY displayed a reduced
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proliferative response. In this regard, Stat1-/- mice exhibited a reduced LI at all three
doses of CHRY tested and reduced epidermal thickness at the highest dose tested
(440 nmol). Figure 19 displays representative H&E and BrdU stained skin sections
from CHRY mice as well as quantitative analyses of both epidermal thickness and LI
following treatment with CHRY.
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Figure 18. Stat1 deficiency had no significant effect on the epidermal
proliferative response following topical application of TPA. Wild-type
(Stat1+/+) or knockout (Stat1-/-) mice received either acetone (vehicle) or TPA
(3.4, 6.8, 13.6nmol) twice weekly for two weeks. Forty-eights hours following
the last treatment the dorsal skin sections were excised and fixed in formalin,
embedded in paraffin, and then sectioned. Sections were cut and stained with
hematoxylin & eosin or anti-BrdU. Epidermal thickness and labeling index (LI)
were determined as described previously.
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Figure 19. Stat1 deficiency resulted in a significant reduction in the
epidermal proliferative response following topical application of CHRY.
Wild-type (Stat1+/+) or knockout (Stat1-/-) mice received either acetone vehicle or
CHRY (100, 220, 440nmol) once weekly for four weeks. Forty-eights hours
following the last treatment the dorsal skin sections were excised and fixed in
formalin, embedded in paraffin, and then sectioned. Sections were cut and
stained with hematoxylin & eosin or anti-BrdU. Epidermal thickness and labeling
index (LI) were determined as described previously.
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5.4 Impact of Stat1 deletion on epidermal differentiation markers following
treatment with CHRY.
Epidermal differentiation plays an important role in the process of tumor
development. Differentiation is characterized by quiescence at the G1 phase of the cell
cycle (104) therefore differentiation represses the cells ability to respond to growth
factors (105). Based on the data that Stat1-/- mice were highly resistant to tumor
formation by CHRY and the data in Figure 19 showing reduced proliferation, Stat1-/mice were compared with wild-type mice for any changes in differentiation marker
expression following treatment with this tumor promoter. To evaluate epidermal
differentiation, Stat1 wild-type and Stat1 -/- mice were treated once topically with 220
nmol CHRY and sacrificed 18 hrs following treatment. Whole skin sections were
excised then fixed in formalin and paraffin embedded. To assess keratinocyte
differentiation we evaluated several common epidermal markers of differentiation
including K5 (basal), K1 (suprabasal), K10 (suprabasal), loricrin (late state
differentiation) and K6 (proliferation/hair follicle). As shown in Figure 20, the absence
of Stat1 did not appear to significantly affect expression of the selected differentiation
markers following treatment with CHRY.
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Figure 20. Stat1 deficiency had no significant effect on epidermal differentiation
following topical application of CHRY compared to controls. Stat1 KO (Stat1-/-) mice
and wild-type mice 6-8 weeks of age received either a single topical application of acetone
or 220nmol CHRY in 0.2 ml. Mice were sacrificed at various time points and whole skin
sections were prepared to assess epidermal differentiation. Representative sections of
whole skin sections stained with K5, K1, K10, Loricrin and K6 are shown.
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Chapter 6 Role of IFNγγ Signaling in Activation and upregulation of Stat1

Rationale
Type I and II IFNs represent a class of pleiotropic cytokines with diverse functions
that are context and cell specific. IFNs play a vital role in the innate and humoral
immune response to deal with invading pathogens. IFNs are activated by a variety of
stimuli and once activated they drive the expression of genes important for clearance of
pathogens (e.g. IRF-1, OAS, iNOS). The expression of IFNs in response to tumor
promoter treatment is not well established. The aim of this study was to examine IFN
signaling following treatment with both TPA and CHRY and determine its role in
activation of Stat1 observed following treatment with these promoters.

6.1 Examination of IRF1 expression following treatment with diverse tumor
promoters.
In light of the data in Figure 8 showing induction of uStat1 following treatment of
mouse epidermis with CHRY, we examined the status of IRF-1. IRF-1 is an IFN-γ/pStat1 responsive transcription factor that is known to regulate expression of a variety of
genes, including uStat1 (106). Stat1-/- mice and wild-type controls were treated topically
using a multiple treatment regimen involving 4 treatments with either acetone, 6.8 nmol
TPA (2x/week for two weeks) or 220 nmol CHRY (1x/week for four weeks) as
described above. Mice were sacrificed at the specified time points and epidermal
lysates were prepared for protein analysis by Western blot or RNA analysis by q-RTPCR as described in the Materials and Methods section. As shown in Figure 21, IRF-1
protein levels decreased in both wild-type and Stat1-/- epidermal lysates following TPA
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treatment. In addition, IRF-1 mRNA levels were not induced in response to TPA in
epidermis of either genotype. On the other hand, CHRY treatment led to an increase in
IRF-1 expression at both mRNA and protein levels (Figure 21B). Quantitation of IRF-1
protein shows an approximate 3-fold increase of IRF-1 in wild-type controls as early as
6 hours following treatment with CHRY. Consistently, an increase in IRF-1 mRNA was
observed by q-RT-PCR, peaking at 6 hrs and tapering off 24 hrs after treatment with
CHRY. Interestingly, Stat1-/- mice were highly resistant to IRF-1 induction by CHRY.
Examination of epidermal lysates from Stat1-/- mice showed that loss of Stat1
abrogated the induction of IRF-1 mRNA and protein following treatment with CHRY as
observed in wild-type controls (panel B).
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Figure 21. CHRY treatment led to an increase in IRF-1 expression, whereas TPA
decreased IRF-1 levels. Wild-type (Stat1+/+) or knockout (Stat1-/-) mice received
either A) TPA (6.8 nmol 2x/week for 2 weeks) or B) 220 nmol CHRY (1x/week for 4
weeks) in 0.2 mL acetone (Ace). Mice were sacrificed at the indicated time points and
epidermal lysates prepared for IRF-1 protein (Western blot) and mRNA expression
(qPCR) analyses. Total protein levels were quantitated by densitometry. Actin was
used to normalize protein loading. Western blot data are from a single experiment
(pooled protein samples) that has been repeated with similar results. The mRNA data
was obtained from individual mice (n=3-5/group) allowing statistical analysis. *
indicates values between Stat1+/+ and Stat1-/- groups were significantly different
(Mann Whitney U, p≤0.05).
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6.2 Examine the role of IFN signaling on Stat1 activation following treatment with
TPA and CHRY.

The data shown in Figure 8 suggested that CHRY treatment influenced Stat1
signaling via a different pathway than TPA, possibly involving IFNγ signaling. This was
substantiated by examining IRF-1 status as shown in Figure 21. Collectively these data
suggested that CHRY upregulated IFNγ signaling. In light of these findings, we sought
to determine how these two mechanistically different tumor promoters influence
production of both Type I and II IFNs. Therefore, the expression of IFNα, IFNβ, and
IFNγ was examined following treatment with both TPA and CHRY. For these
experiments, Stat1-/- and wild-type mice were again treated using a multiple treatment
protocol as described above. As shown in Figure 22, TPA treatment did not induce
epidermal IFNγ mRNA expression and, in fact, a statistically significant decrease was
observed at all time points examined (panel A). In contrast, a significant increase in
IFNγ mRNA levels at 3, 6 and 12 hours after treatment with CHRY, with a peak at
approximately 3 hrs after the last treatment (~8-fold increase compared to acetone
treated control mice) (Figure 22 panel B). Thus, induction of IFNγ was observed by
treatment with CHRY but not following treatment with TPA.
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Next we wanted to examine the levels of Type I IFNs, to determine if they played a role
in tumor promotion following tumor promoter treatment. As shown in Figure 23, there
were no significant increases in the Type I (α and β) IFNs following treatment with TPA
and again like IFNγ the mRNAs for these two IFNs actually decreased after treatment.
Following treatment with CHRY, there was a slight increase in IFNα mRNA at 6 hrs
(p<0.05) but not at other time points and there were no increases seen in IFNβ mRNA.
Collectively, these data indicate the Stat1 activation and upregulation of IRF-1 in
epidermis is associated with significant upregulation of IFNγ mRNA and together these
data demonstrate that CHRY activates IFNγ signaling whereas TPA does not.

Based on the data obtained in Figures 22 and 23, we hypothesized that CHRYmediated tumor promotion was dependent on a IFNγ/p-Stat1/IRF-1 signaling pathway,
via induction of IFNγ ligand and activation of IFNγR1, whereas this pathway is not
involved in skin tumor promotion by TPA. To further test this hypothesis we employed
the use of IFNγR1 knockout mice (IFNγR1-/-). IFNγR1-/-and control mice were treated
using a multiple treatment regimen as described above. As shown in Figure 24, topical
treatment with TPA did not induce IRF-1 mRNA in either wild-type or IFNγR1-/- mice. In
contrast, a significant increase in IRF-1 mRNA levels was observed in wild-type mice
but not in IFNγR1-/- mice following treatment with CHRY. Furthermore, topical
treatment with TPA did not increase Stat1 mRNA levels in either wild-type or IFNγR1-/mice. However, CHRY treatment caused an approximate 2-fold increase in Stat1
mRNA 24 hrs following treatment. These data demonstrate that induction of IFNγin the
epidermis by CHRY leads to induction of IRF-1 and uStat1 via signaling through
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IFNγR1.
To further validate our findings, we used Stat1-/- primary keratinocytes and recombinant
mouse IFNγrIFNγas a surrogate for CHRY treatment in these cells. Primary
keratinocytes were harvested as described in the Material and Methods section and
placed in starvation media for 24 hrs prior to stimulation. As shown in Figure 25,
treatment of wild-type keratinocytes with rIFNγand TPA increased phosphorylation of
Stat1Y701 Phosphorylation of Stat1occured rapidly in response to rIFNγ treatment
compared to TPA. In addition, stimulation of primary keratinocytes with rIFNγ resulted
in a significant increase in IRF-1 protein levels within 3 hours following treatment in
wild-type, but not Stat1-/- keratinocytes. In contrast, IRF-1 expression was unaffected
in both wild-type and Stat1-/- keratinocytes, following treatment with TPA, in spite of
increased phosphorylation of Stat1Y701 in wild-type keratinocytes. In addition, we
observed an increase in total Stat1 protein levels in rIFNγ but not TPA-treated wild-type
keratinocytes. These data confirm that keratinocytes respond to rIFNγ and TPA
treatment in a manner similar to that observed in mouse epidermis in vivo and support
the hypothesis that CHRY works via upregulation of the IFNγ signaling pathway.
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Figure 22. CHRY treatment led to increased levels of IFNγγ whereas
TPA resulted in a decrease. Wild-type mice 6-8 weeks of age received
topical applications of acetone (Ace), TPA (6.8 nmol 2x/week for 2 weeks)
or CHRY (220 nmol 1x/ week for 4 weeks). Mice were sacrificed at the
indicated time points and epidermal mRNA expression was analyzed by
qPCR. A) IFNγ mRNA levels following TPA and B) IFNγ mRNA levels
following CHRY treatment +indicates values significantly different from the
Ace control;(Mann Whitney U, p≤0.05.
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Figure 23. Following tumor promoter treatment Type I (α
α and β ) Interferons
levels decreased compared to acetone controls. Wild-type mice 6-8 weeks of
age received topical applications of acetone (Ace), TPA (6.8 nmol 2x/week for 2
weeks) or CHRY (220 nmol 1x/ week for 4 weeks). Mice were sacrificed at the
indicated time points and epidermal mRNA expression was analyzed by qPCR. A)
Type I IFN mRNA levels following TPA treatment; B) Type I IFN mRNA levels
following CHRY treatment * indicates values significantly different from the Ace
control;(Mann Whitney U, p≤0.05).

75

A

B

TPA

TPA

CHRY

CHRY

Figure 24. CHRY treatment led to activation of the IFNγγ-Stat1 signaling axis
whereas TPA resulted in a decrease. Wild-type and IFNγR1 knock-out mice 6-8
weeks of age received topical applications of acetone (Ace), TPA (6.8 nmol 2x/week
for 2 weeks) or CHRY (220 nmol 1x/ week for 4 weeks). Mice were sacrificed at the
indicated time points and epidermal mRNA expression was analyzed by qPCR. A)
IRF-1 mRNA levels following TPA and CHRY treatment; B) Stat1 mRNA levels
following TPA and CHRY treatment. + indicates values significantly different from the
Ace control; * indicates values between KO and wild-type mice were significantly
different (Mann Whitney U, p≤0.05).
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Figure 25. Primary keratinocytes stimulated with IFNγγ led to an induction of
IRF-1. Primary keratinocytes were isolated from Stat1 wild-type and Stat1-/- mice and
cultured by methods described in the Material and Method section. Primary
keratinocytes were stimulated with either TPA (680 nM) or IFNγ (250ng/ml).
Untreated cultured primary keratinocytes served as control. Keratinocytes were
stimulated for the indicated time point and harvested. Protein lysates were prepared
for Western Blot analysis.
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Chapter 7. IFNγγ/pStat1/IRF-1 signaling axis regulates inflammation and
inflammatory signaling induced by CHRY

Rationale
As noted in the Introduction inflammation has long been associated with cancer
development. The JAK-STAT pathway is indispensible for innate as well as adaptive
immunity, but persistent activation of these immunological response pathways may
lead to chronic inflammation. During a state of chronic inflammation in the skin,
activated immunocytes are recruited to the area where they produce copious amounts
of pro-inflammatory cytokines such as IL-6 [reviewed in (107)], TNFα [reviewed in(108)
and IFNγ [reviewed in(109). Based on the data presented in Chapters 5 and 6, a role
for the IFNγ/pStat1/IRF-1 signaling axis in CHRY-mediated tumor promotion has been
presented. The aim of the studies in this chapter was to evaluate the potential role of
this signaling pathway in inflammation and inflammatory signaling pathways associated
with skin tumor promotion by CHRY. For these studies we again used Stat1-/- mice.

7.1. Impact of Stat1 deficiency on NF-κ
κB and Cox-2 following treatment with TPA
and CHRY

To further explore potential mechanism(s) whereby IFNγ/pStat1/IRF-1 signaling
mediates skin tumor promotion by CHRY, we examined the impact of Stat1 deficiency
on NF-κB activation and Cox-2 expression following treatment with TPA and CHRY.
For these experiments, wild-type and Stat1-/- mice were again treated using a multiple
treatment protocol with either 6.8 nmol TPA or 220 nmol CHRY as described above.
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Mice were sacrificed at the indicated time points following the last treatment.
Epidermal lysates where collected for protein analysis by Western blot and analysis of
mRNA by q-RT-PCR. As shown in Figure 26, topical treatment with TPA led to an
increase in Cox-2 expression (both mRNA and protein) as early as 6 hrs after the last
treatment in both wild-type and Stat1-/- mice. In contrast, Stat1-/- mice exhibited a
significant reduction in Cox-2 expression compared to the wild-type controls following
treatment with CHRY. In this regard, Stat1-/- mice exhibited an approximate 3-fold
reduction in Cox-2 protein levels and an even greater reduction in Cox-2 mRNA at the
12 hr time point compared to wild-type controls treated with CHRY (panel B). The
observed reduction in levels of Cox-2 in Stat1-/- mice persisted until levels reached
baseline values at 48 hrs following treatment with CHRY. Consistent with significant
reductions in Cox-2 protein levels, Stat1-/- mice treated with CHRY exhibited a decrease
in epidermal PGE2 levels compared to wild-type mice, whereas no differences in
epidermal PGE2 levels were observed between the two genotypes treated with TPA
(Figure 27). Since NF-κB has previously been linked to Cox-2 expression in mouse
epidermis, we evaluated whether the reduction in Cox-2 expression was associated
with reduced NF-κB signaling after CHRY treatment. Interestingly, activation of NF-κB
signaling (measured by phosphorylation at Ser536) was similar in wild-type and Stat1-/mice after treatment with CHRY. As shown in Figure 26 panel C, the reduced
expression of Cox-2 in epidermis of Stat1-/- mice seen following treatment with CHRY
occurred in the presence of normal NF-κB signaling.
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Figure 26. Impact of Stat1 deficiency on the promoter-induced Cox-2 and NF-κ
κB
expression. Wild-type (Stat1+/+) or Stat1 knock-out (Stat1-/-) mice received 4 topical
applications of either acetone (Ace), 6.8 nmol TPA, or 220 nmol CHRY and were
sacrificed at the indicated time points. Epidermal lysates were prepared for protein
analysis by Western blot and mRNA expression was examined by qPCR. Cox-2
expression following A) TPA; and B) CHRY treatment; C) NF-κB signaling following
CHRY treatment. Western blot data are from a single experiment (pooled protein
samples) that has been repeated with very similar results. The mRNA data was
obtained from individual mice (n=5/group) allowing statistical analyses. * indicates
values between Stat1+/+ and Stat1-/- groups were significantly different by MannWhitney U (p≤0.05).
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Figure 27. Effect of Stat1 deficiency on prostaglandin E2 (PGE2)
synthesis following tumor promoter treatment. Wild-type (Stat1+/+)
or knockout (Stat1-/-) mice received either a single 220 nmol dose of
chrysarobin CHRY in 0.2 mL acetone (Ace) or four applications of TPA
(6.8 nmol 2x/week for 2 weeks). Following indicated time after last
treatment the dorsal skin was excised and snap frozen with liquid
nitrogen. Pooled frozen epidermis from 3-4 mice was chipped into
PGE2 lysis buffer. PGE2 was eluted and assayed using manufacturer
instructions.
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7.2 Effect of Stat1 deficiency on iNOS expression and following topical treatment
with TPA and CHRY.
iNOS is a Stat1 responsive gene that is responsible for the production of the
reactive oxygen radical nitrous oxide (NO). iNOS overproduction and the production of
NO is associated with pathological conditions of inflammation (110) (111, 112) and
tumor development (113). Therefore, we also determined the impact of Stat1 deficiency
on the expression of iNOS in response to treatment with TPA and CHRY. As shown in
Figure 28 (panel A), topical treatment with TPA led to an increase in iNOS mRNA
levels at 6 hrs, which quickly returned to basal levels at 18 hrs following treatment.
Furthermore, no differences were observed in the response of Stat1-/- mice compared
to wild-type control mice following treatment with TPA. In contrast, treatment with
CHRY led to a significant increase in iNOS mRNA levels in wild-type mice, but Stat1-/mice where highly resistant to iNOS induction (Figure 28, panel B). CHRY treatment
led to a rapid increase in mRNA levels of iNOS as early as 6 hrs that remained
elevated until iNOS reached basal levels at 48 hrs following treatment in wild-type mice.
iNOS mRNA levels peaked around 12 hrs following treatment with CHRY: There was
an approximate 10-fold increase in iNOS mRNA at this time point in wild-type
compared to Stat1-/- mice.
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Figure 28. Stat1 deficient mice were resistant to iNOS induction following
CHRY treatment, whereas TPA-mediated induction of iNOS occurs
independent of Stat1 Wild-type (Stat1+/+) or knockout (Stat1-/-) mice received
either A) TPA (6.8 nmol 2x/week for 2 weeks) or B) 220 nmol CHRY (1x/week for
4 weeks) in 0.2 mL acetone (Ace). Epidermal lysates were prepared at the
indicated time points for mRNA analysis by qPCR. The mRNA data was obtained
from individual mice (n=3-5/group) allowing statistical analysis. * indicates value
was significantly different from control (Mann Whitney U, p≤0.05).
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7.3 Stat1 deficiency results in attenuated dermal infiltration of macrophages
following treatment with CHRY
Chronic inflammation is characterized by the infiltration of immunocytes. This
influx of immune cells represents a double-edge sword in that it has anti-tumorigenic as
well as pro-tumorigenic effects. As mentioned previously, Stat1 has been shown to be
a vital player in the immune response, representing the major transducer of both Type
1 and Type II IFNs. Stat1 is rapidly activated in macrophages in response to treatment
with lipopolysaccharide (LPS), a bacterial cell wall component that is a potent activator
of immunocytes (114). In addition, Stat1 regulates the expression of many
chemoattractant chemokine/cytokines such as monokine induced by IFNγ (MIG), CC
chemokine ligand-20 (CCL-20), epithelial cell- derived neutrophil-activating peptide
(ENA-78) and IFN-inducible T cell-chemoattractant (I-TAC) (53). To examine the
impact of Stat1 deletion on immune cell infiltration, Stat1-/- and wild-type control mice
were evaluated for immune cell influx of various immunocytes by
immunohistochemistry (leukocytes, mast cells, neutrophils, and macrophages).
Groups of 3-4 mice of each genotype were treated once with 220 nmol CHRY and
sacrificed at the indicated time points. Qualitative immunohistochemistry studies
revealed that Stat1 deficiency resulted in a decrease of macrophage infiltration into the
dermal compartment of Stat1-/- mouse skin after treatment with CHRY compared to
wild-type control mice (see Figure 29). The differences in macrophage influx were
most evident during the earlier time points examined (6 and 12 hour). There were no
noticeable differences seen in the infiltration of Tcells, mast cells or neutrophils (data
not shown).
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Figure 29. Stat1 deficient mice displayed a reduced dermal inflammatory response (decreased macrophages)
following topical application of CHRY compared to controls. Stat1 KO (Stat1-/-) mice and wild-type (Stat1+/+) mice
6-8 weeks of age received either a single topical application of acetone or 220nmol CHRY in 0.2 ml. Mice were
sacrificed at the indicated time points and whole skin sections were prepared to assess immune cell infiltration.
Representative sections of whole skin sections were stained with S100A8 are shown.
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7.4 Stat1 is necessary for expression of inflammatory chemokine/cytokines
induced by CHRY
Chemokines/cytokines play a vital role in tumor development. Chronic
inflammation promotes tumor development by inducing a cascade whereby both tumor
cells and stromal cells produce various chemokines and cytokines [reviewed in (115,
116)]. These various chemokines and cytokines may act in an autocrine or paracrine
fashion to sustain tumor growth, induce angiogenesis, or facilitate evasion of immune
surveillance by immunoediting. Chemokines are classified into four groups, CXC, CC,
CX3C and C, which is based on the positioning of the conserved two N-terminal
cysteine residues (117). To further evaluate the role of Stat1 in the production of
chemokines and cytokines induced by CHRY, we utilized a real-time based
inflammatory panel assay described in the Materials and Methods section and, mRNA
isolated 6 hrs after the last of 4 treatments with CHRY. As shown in Figure 30, the
absence of Stat1 led to a significant reduction in expression of several inflammatoryassociated chemokines/cytokines (>2-fold) reduction compared to wild-type control
mice following treatment with CHRY.
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Figure 30. Stat1 deficiency caused a significant decrease in several inflammatory
mediators following CHRY treatment. Four to five Stat1+/+ (solid black) or Stat1-/- (white)
mice received 4 topical applications of 220nmol CHRY and were sacrificed 6 hrs following
the last treatment. RNA was isolated from epidermal lysates as previously described in the
Material and Methods section. mRNA expression was analyzed by RT2 Profiler
inflammatory cytokine/chemokine array (SA Bioscience) using manufacturer instructions.
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Chapter 8: Ongoing and Future studies
8.1 Stat1 and UV carcinogenesis
In terms of human relevance, UV radiation (UVR) represents the major
risk factor for skin cancer. Acute exposure to UVR induces cell damage and
induces DNA repair pathways. Chronic exposure leads to increased epidermal
damage, increased hyperplasia, and inflammation and skin cancer. Skin cancer
represents the most common cancer in humans today, with steadily increasing
rates in new cases. UVR is subdivided into UVA (315-400nm), UVB (290315nm) and UVC (100-280nm). The solar output that reaches the earth’s surface
is approximately 95-98% UVA and 2-5% UVB, while UVC is completely absorbed
by the stratospheric layer of the ozone. Although UVA is much more abundant,
several studies have determined that wavelengths in the range of 295 nm to
305nm (UVB) are the most important in influencing tumor development.
[reviewed in(118)]. However UVA has been shown to posses both weak
complete carcinogenicity and moderate skin tumor promotion ability [reviewed
in(119)]. It should also be noted that solar radiation is more effective at inducing
skin tumors in experimental animals than UVB alone further implicating a role for
UVA in human skin cancer.

Stat3 has been shown to play an important role in UVB-mediated skin
carcinogenesis by modulating cell proliferation and apoptosis [reviewed in (118,
120)]. In contrast, the role of Stat1 during UVB-mediated skin carcinogenesis
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remains largely unknown. Studies by Zhang et al report that following UVB
irradiation, Stat1 is phosphorylated on its serine 727 residue, and not its Y701
residue (121). As shown in Figure 31, preliminary data has confirmed that
following a single exposure to 350 mJ/cm2 UVB, Stat1 S727 phosphorylation
occurs as early as 3 hours in epidermis of FVB/N wild-type mice. In contrast,
there was no detectable phosphorylation of Stat1 on Tyr701 (see again Figure
31). Since serine phosphorylation is necessary for maximal transcriptional
activity of STATs, it will be interesting to examine the transcriptional activity of
Stat1 in the absence of tyrosine phosphorylation. Studies are underway to fully
characterize the role Stat1 in response to UVB irradiation.
In addition to investigating UVB, we also plan to investigate UVA. Data in
the literature indicate that UVA exposure alone can induce skin papillomas and
SCCs in mouse skin although with weaker activity that UVB (122). Additional
studies with UVA suggest that it produces biochemical and molecular changes in
mouse skin similar to other types of tumor promoters (123) and that it possess
tumor promoting activity in vivo (124). A previous study reported that UVA (320400 nm) but not UVB (280-320 nm) irradiation of mouse skin led to the induction
of IFNγ in epidermis of hairless mice (125). Furthermore, low dose UVA
irradiation of cultured human keratinocytes led to activation (DNA binding activity
and tyrosine phosphorylation) of Stat1 (126). These data suggest the possibility
that UVA exposure may activate a similar signaling pathway involving IFNγ/Stat1/IRF-1 that may contribute to its tumor promoting activity. Studies are currently
underway to investigate the role of UVA irradiation on the IFNγ/pStat1/IRF-1
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signaling axis. For these experiments Stat1 wild-type and Stat1-/- will be
irradiated with UV (UVA or UVB) and the impact of Stat1 deletion on signaling
pathways, apoptosis, proliferation, and tumor development will be examined.
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Figure 31. Effect of UVB exposure on Stat1. FVB/N wild-type mice 6-8 weeks of age
were exposed to 350mJ/cm2 of UVB irradiation. Mice were sacrificed at the indicated
timepoint following irradiation. Untreated mice served as the control. Mice were
sacrificed at the indicated time points and epidermal lysates were prepared for protein
analysis by Western blot.
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8.2 Possible role of IFNγγ/pStat1/IRF-1 signaling in tumor promotion by other
non-phorbol ester promoters
Benzoyl Peroxide (BzPo) is an organic peroxide that is commonly used in
cosmetic and pharmaceutical industries, in particular in the form of acne
medication. BzPo is another non-phorbol ester skin tumor promoter that forms
radicals upon breakdown (69, 127). The generation of such radicals is believed
to be critical to its mechanism of skin tumor promoting action (128-130). BzPo
induces short-term biomarkers commonly associated with tumor development
such as ODC induction and increased epidermal hyperplasia,(131). Thus, BzPo
and CHRY share some similarities in this regard. Preliminary data from our lab
(see Figure 32), show that a single topical application of BzPo (20 mg/mouse) led
to activation of Stat1 (phosphorylation at both Tyr701 and Ser727) at several time
points after treatment. In addition, Stat1 protein levels were significantly elevated
at later time points (48, 72 and 96 hrs) after treatment. These results are very
similar to those obtained with CHRY suggesting that BzPo may work, at least in
part through activation of the IFNγ/pStat1/IRF-1 signaling pathway. We are
currently determining the extent to which this pathway applies to the promoting
action of BzPo and possibly other free radical generating skin tumor promoters.
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Figure 32. Effect of BzPo treatment on Stat1 phosphorylation/induction
in mouse epidermis. Wild-type FVB/N mice 6-8 weeks of age received a
single application of acetone (Ace) or 20 mg BzPo. Mice were sacrificed at the
indicated time points and epidermal lysates were prepared for protein analysis
by Western blot. Protein levels were quantitated by densitometry. Actin was
used to normalize protein loading. phospho-Stat levels were normalized to
total Stat1.
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8.3 Cellular source of IFNγγ production following treatment with CHRY
As shown in Figure 22, treatment with CHRY caused a rapid increase in
IFNγ mRNA in the epidermis. At the present time we are unsure of the source of
the IFNγ production. Although keratinocytes express the IFNγ receptor it is not
clear whether keratinocytes are capable of producing IFNγ. The majority of IFNγ
is produced by the activated immunocytes [reviewed in(132)]. Based on the
findings that IFNγ mRNA is induced rapidly, it is likely that it is resident
immunocytes of the epidermis. Cells that reside in the epidermis include
langerhans cells (LCs) and dendritic cells, especially γδ T cells(133). γδ T cells
are known to produce IFNγ (134) and it is possible that these cells or other
resident T-cells are responsible for the increase in IFNγ mRNA seen in epidermal
RNA samples following treatment with CHRY. Utilizing flow cytometry methods,
cells will be sorted based on immune subtype specific surface markers. Once
pure populations of the various cell types are acquired, the IFNγ production will
be evaluated by intracellular cytokine staining.
8.4 Studies using epidermis specific Stat1 deficient mice
To date all experiments regarding Stat1 have been performed utilizing
mice with deletion of Stat1 in all cells of the body (93). Thus, some of the effects
of Stat1 deletion on skin tumor promotion by CHRY could be due to loss of Stat1
in other cells, e.g. immune/inflammatory cells. Stat1-/- mice are known to have
some defects in immune response (94) as well as defects in cytokine production
(51). In future studies, BK5.Cre x Stat1flox/flox mice will be used to evaluate the
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impact of Stat1 deletion on epidermal proliferation and skin inflammation induced
by CHRY. Keratinocyte specific deletion of Stat1 will allow us to determine if the
effects of Stat1 are cell autonomous to keratinocytes or are a result of the
resident populations of immunocytes.
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Chapter 9: Discussion

In the current study, we examined the role of Stat1 in tumor promotion and
epithelial carcinogenesis utilizing the well-established two-stage skin
carcinogenesis model (54). The results demonstrate that topical application of
both TPA and CHRY led to activation of Stat1 (phosphorylation at both Y701 and
S727). Furthermore, topical application of CHRY caused a significant increase in
total uStat1 protein level whereas TPA did not. Further mechanistic studies
revealed that treatment with CHRY led to upregulation of signaling via IFNγ and
that this was responsible for a significant portion of epidermal Stat1 activation as
well as upregulation of uStat1 following treatment with this tumor promoter.
Utilizing the two-stage skin carcinogenesis model, the importance of this
signaling pathway in skin tumor promotion by CHRY was further demonstrated
using Stat1-/- mice. Stat1-/- mice were highly resistant to skin tumor promotion by
CHRY but not TPA, indicating an absolute requirement for this pathway for tumor
promotion by anthrone tumor promoters. Collectively, the current data
demonstrate a novel mechanism of skin tumor promotion involving IFNγ-pStat1IRF-1 signaling and upregulaton of uStat1 in keratinocytes for the anthrone class
of skin tumor promoters of which CHRY is the most potent member (135). This
pathway does not play a major role in skin tumor promotion by the phorbol ester,
TPA.
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In earlier studies from our laboratory, we reported that Stat1 activation
(Y701 phosphorylation) along with Stat3 activation (Y705 phosphorylation)
occurred in epidermis following topical treatment with TPA (99). It was also
shown that Stat1 phosphorylation was elevated in papillomas generated by a
standard two-stage DMBA/TPA protocol (99). The activation of Stat3 in
keratinocytes was shown to be dependent on signaling through the EGFR
although the mechanism for activation of Stat1 by TPA was not further
investigated. As shown in Figure 8, treatment with both TPA and CHRY led to
rapid activation of Stat1 in epidermis. However, treatment with CHRY also led to
a significant upregulation of uSTAT1 suggesting that there might be fundamental
differences in the mechanism of Stat1 activation between the two compounds.
This hypothesis was borne out by further analyzing the potential role of IFNγ
signaling following treatment with both types of promoters. As noted in the
introduction, a major pathway for activation of Stat1 in various cells, including
keratinocytes, is via IFNγ receptor signaling (136, 137). As shown in Figures 21
and 24, treatment with CHRY but not TPA led to upregulation of IRF-1 and this
was dependent on IFNγ receptor signaling via Stat1.

The data in the current paper represent the first report that topical
treatment with CHRY leads to upregulation of IFNγ and IFNγ-receptor signaling in
epidermis. The possible role of IFNγ in skin tumor promotion by TPA has
previously been explored. In earlier studies, Reiners and colleagues reported
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that IFNγ could act as a co-promoter when injected i.p. together with topical
application of TPA (138). IFNγ given alone did not promote skin tumors in mice
initiated with DMBA in these earlier studies. More recently, the role of IFNγ
signaling in tumor promotion by TPA has been explored more directly using
genetically engineered mouse models with conflicting results. In this regard,
Xiao et al reported that IFNγ mRNA levels were elevated in RNA samples
isolated from whole skin following treatment with DMBA and either a single or
multiple treatments with TPA (139). In addition, these authors reported that Stat1
was activated in protein lysates isolated from whole skin 24 hrs following the last
TPA treatment. These authors also reported that administration of an anti-IFNγ
antibody or using of IFNγ receptor deficient mice reduced the number of
papillomas but had no effect on the incidence of SCCs in a two-stage
carcinogenesis protocol. In contrast to these data, Wang et al (137) reported that
IFNγ/- mice had nearly identical tumor response (both the percentage of mice
with papillomas and papillomas per mouse) when compared with wild-type mice
undergoing a two-stage (DMBA-TPA) protocol. Our current data support the
conclusion that IFNγ signaling via Stat1 and IRF-1 is not involved in skin tumor
promotion by TPA. However, the current data may explain the co-promoting
effects if IFNγ as well as previous data showing that low doses of CHRY could
also act as a co-promoter when given together with TPA (135).
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As noted in the Introduction, several reports have indicated a possible protumorigenic role for Stat1 (45, 47, 140) although other studies have supported a
tumor suppressor role for this signaling molecule. In a previous study, Schreiber
et al. reported that following a single subcutaneous injection of the carcinogen
methylcholanthrene (MCA), IFNγR-/- and Stat1-/- mice were highly susceptible to
tumor formation compared to 129/Sv controls (141). In this study they also report
that Stat1 and p53 double knockout mice developed tumors more rapidly and
with greater frequency then p53 single knockout, when challenged with MCA.
Other studies have also shown that IFNγ plays an important role in immune
surveillance for chemically-induced tumors, including skin tumors (141). In
contrast, Hanada et al. (142) reported that mice deficient in Suppressor of
Cytokine Signaling-1 (SOCS1), a negative regulator of STAT signaling,
developed spontaneous colorectal carcinomas and their development was IFNγdependent. In this study, IFNγ-/-SOCS1-/- mice failed to develop tumors
regardless of the upregulation of Stat3 responsive genes such as Bcl-XL and cmyc when compared to the SOCS1-/- deficient mice. These results suggested a
critical role for IFNγ/Stat1 signaling in the development of colorectal tumors in this
mouse model. The current data clearly demonstrate an important role for Stat1
activation via IFNγ signaling in epidermis in mediating skin tumor promotion by
CHRY. Perhaps Stat1 activation via IFNγ signaling has opposing roles during
epithelial carcinogenesis in mouse skin: a pro-tumorigenic role during the early
tumor promotion stage and an immune surveillance function once tumors are
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developed. Further ongoing studies using conditional Stat1 knockout mice will
help to address these ideas in more detail.

The mechanism(s) for how Stat1 mediates skin tumor promotion by CHRY
remain to be fully determined. As shown in Figure 19, Stat1 deficient mice
treated with CHRY had a reduced proliferative response as measured by BrdU
incorporation and epidermal thickness. However, the decrease in epidermal
proliferation seen in Stat-/- mice in response to treatment with CHRY did not
appear sufficient to explain the dramatic inhibition of skin tumor promotion by
CHRY seen in these mice (Figure 16). Stat1 has been shown to regulate the
production of pro-inflammatory molecules such as inducible nitric oxide synthase
(iNOS) and cyclooxygenase-2 (Cox-2)(52, 143). Furthermore, IFNγ is also known
to upregulate a variety of inflammatory mediators including tumor necrosis factor
alpha (TNFα) (144), interleukin-12 (IL-12) (145), gp91phox (146) and iNOS, (147).
IRF-1 is a Stat1 responsive transcription factor that acts as a secondary
response to activate other downstream targets (i.e., iNOS and Cox-2) (52, 148150). As shown in Figure 21, treatment with CHRY also led to upregulation of
IRF-1 that was blocked in both Stat1-/- and IFNγR1 -/- mice (Figures 21 and 24).
Both TPA and CHRY treatment led to upregulation of epidermal Cox-2
expression (both mRNA and protein) (Figure 26). Furthermore, the upregulation
of Cox-2 (and PGE2) by CHRY but not TPA was dependent on activation of Stat1.
Similar results were obtained for the upregulation of iNOS by both compounds
(Figure 28). The reduction in Cox-2 and iNOS expression in Stat1-/- mice
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compared to wild-type mice following treatment with CHRY occurred in the
presence of apparently normal activation of NF-κB (Figure 26, panel C) further
demonstrating the importance of Stat1 signaling in mediating skin tumor
promotion by CHRY. The induction of Cox-2 and the increased production of
prostaglandins such as PGE2 represent important events in the process of skin
tumor promotion (90, 151, 152). Therefore, Stat1/IRF-1 regulation of the
induction of Cox-2 (and possibly iNOS) by CHRY may explain, at least in part,
some of the mechanism associated with skin tumor promotion by this compound.

Another interesting observation in the current study was the induction of
uStat1 by CHRY but not TPA (Figure 8). Recently, it was found that Stats 1 and 3
(and possibly other Stats) also play important roles in mediating gene expression
in the absence of tyrosine phosphorylation (39, 40), Stat1 and Stat3 genes are
targets of activated (phosphorylated) Stat1 and Stat3 proteins, respectively (41).
As a result, cytokine activation of Stat1 or Stat3 (e.g., IFNγ or IL-6, respectively),
leads to the induction and accumulation of uStats 1 and 3, which may persist for
days after p-Stat levels have subsided (40). In addition, induction of the Stat1
target gene, IRF-1, aids in the continued accumulation of uStat1 in response to
IFNγ. It is well documented that uStats 1 and 3 can act as transcription factors
and regulate a subset of genes that are different from those regulated by p-Stats
(39, 42, 153). Together these data suggest that uStat1 may be transcriptionally
active and play a significant role in skin tumor promotion by CHRY.
Transcriptional profiling has shown that the majority of uStat1 target genes are
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antiviral immune response genes, however uStat1 also induces a subset of
genes implicated in radio- and chemo-resistance in cancer cells (42, 43).
Disruption of interferon effector molecule 8 (IRF8) in soft tissue sarcoma cells
leads to the accumulation of uStat1 (44) and promotes sarcoma cell metastasis
by regulating gene transcription of apoptosis regulators Fas and Bad (44).
However, the role and mechanism(s) by which uStat1 mediates a protumorigenic effect are largely unknown. Future studies are aimed at defining the
role of uStat1 in skin tumor promotion by CHRY and possibly other skin tumor
promoters.

An additional noteworthy aspect of the current studies involves the
potential cellular source of epidermal IFNγ induced by treatment with CHRY.
Although keratinocytes are known to express IFNγ receptors(154), there is little
evidence in the literature suggesting that these cells produce IFNγ. Other cells
that reside in the epidermis include Langerhans cells (LCs) and dendritic cells,
especially γδT cells. γδT cells are known to produce IFNγ (155, 156) and it is
possible that these cells or other resident or recruited T cells may be responsible
for the increase in IFNγ mRNA seen in epidermal RNA samples following
treatment with CHRY. Ongoing studies are aimed at determining the cells in the
epidermis responsible for production of IFNγduring tumor promotion by CHRY.
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In conclusion, the current data identify a novel mechanism for skin tumor
promotion involving activation of IFNγ signaling via p-Stat1 and IRF-1 that is
required for the skin tumor promoting activity of CHRY, a member of the
anthrone class of skin tumor promoters. This mechanism does not appear to play
a major role in skin tumor promotion by the phorbol ester, TPA. The
mechanisms may involve the canonical pathway involving formation of p-Stat1
homodimers, which lead to direct transcriptional regulation of IRF-1 and uStat1.
Alternatively, or in addition, this could involve a non-canonical pathway involving
the translocation of a complex containing IFNγR1-JAKS1/2-p-Stat1 to the nucleus
where it binds to the IRF-1 promoter and induces transcription of IRF-1 (157,
158). Upregulated IRF-1 then leads to increased transcription of a number of
genes, including uStat1, iNOS and Cox-2 as well as others that ultimately
contribute to the skin tumor promoting action of CHRY. Furthermore, both pStat1 and IRF-1 have been shown to interact with NF-κB (159), and that may
also play a role in altered expression of some genes. Figure 33 proposes a
working model for the role of IFNγ/p-Stat1/IRF-1 signaling in skin tumor
promotion by CHRY encompassing these various aspects discussed above.

The current data also support other emerging data in the literature that,
under certain circumstances, Stat1 can have a pro-tumorigenic function. In this
regard, the current studies demonstrate that Stat1 influences epithelial multistage
carcinogenesis early during the process of tumor promotion with certain types of
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chemical tumor promoters. The extent to which this mechanism applies to other
types of chemical tumor promoters, especially those that work primarily through
the generation of free radicals (e.g., BzPo) is currently under investigation.
Further understanding of the downstream effectors of this novel skin tumor
promotion pathway will aid in our understanding of the process of tumor
promotion in general and in the identification of novel targets for cancer
prevention.
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Figure 33. Working Model For the Role of IFNγγ/pStat1/IRF-1 Signaling in Skin Tumor Promotion by CHRY
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